var title_f35_47_36592="HPS all-cause mortality";
var content_f35_47_36592=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F50534&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F50534&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 636px\">",
"   <div class=\"ttl\">",
"    Effect of simvastatin allocation on all-cause mortality in participants subdivided by presenting features",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 616px; height: 506px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of: Heart Protection Study Collaborative Group. The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial. BMC Med 2005; 3:6. Copyright &copy;2005 BioMed Central.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_47_36592=[""].join("\n");
var outline_f35_47_36592=null;
var title_f35_47_36593="CT scan insufficiency fracture of the sacrum";
var content_f35_47_36593=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F85974&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F85974&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    CT scan insufficiency fracture of the sacrum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 249px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The CT scan of the pelvis reveals a subtle fracture of the left sacral ala&nbsp;(A, red arrow) and is magnified and highlighted in B.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gregory Waryasz, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_47_36593=[""].join("\n");
var outline_f35_47_36593=null;
var title_f35_47_36594="Chondroitin sulfate-sodium hyaluronate: Drug information";
var content_f35_47_36594=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Chondroitin sulfate-sodium hyaluronate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/10/20643?source=see_link\">",
"    see \"Chondroitin sulfate-sodium hyaluronate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F151056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      DisCoVisc&reg;;",
"     </li>",
"     <li>",
"      Viscoat&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F151063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Ophthalmic Agent, Viscoelastic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F151057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Surgical aid:",
"     </b>",
"     Ophthalmic: Carefully introduce (using a 27-gauge cannula) into anterior chamber during surgery",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F151058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F151045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution, intraocular:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     DisCoVisc&reg;: Sodium chondroitin sulfate &le;4% and sodium hyaluronate &le;1.7% (1 mL) [provided in a kit which also contains 27-gauge cannula and cannula locking ring]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Viscoat&reg;: Sodium chondroitin sulfate &le;4% and sodium hyaluronate &le;3% (0.5 mL, 0.75 mL) [packaged with 27-gauge cannula and cannula locking ring]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F151033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F151047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Consult specific product instructions on preparing ophthalmic device for use and administration by physician during surgery. May inject in the anterior segment of the eye prior to or following delivery of the crystalline lens. Instillation prior to lens delivery provides additional protection to corneal endothelium, protecting it from possible damage arising from surgical instrumentation. May also be used to coat intraocular lens and tips of surgical instruments prior to implantation surgery. May inject additional solution during anterior segment surgery to fully maintain the solution lost during surgery. At the end of surgery, remove solution by thoroughly irrigating and aspirating with a sterile irrigating solution (eg, balanced salt solution).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F151046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic surgical aid in the anterior segment  during cataract extraction and intraocular lens implantation",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F151061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined: Ocular: Intraocular pressure increased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F151050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to chondroitin, hyaluronate, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F151037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elevated intraocular pressure: Intraocular pressure may be elevated as a result of pre-existing glaucoma, compromised outflow, and by operative procedures and sequelae.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity: Potential risk of hypersensitivity may exist to the use of any biological material.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Do not overfill the anterior chamber; carefully monitor IOP, especially during the immediate postoperative period. For intraocular use only; serious eye injury may occur if proper assembly using cannula and cannula locking ring are not followed or alternate cannula is used.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (DisCoVisc Intraocular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40-17 mg/mL (1 mL): $260.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Viscoat Intraocular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40-30 mg/mL (0.5 mL): $156.40",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F11390210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Viscoat (AU, NZ)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F151036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic viscosurgical device which modulates the interactions between adjacent tissues by space creation, tissue stabilization, balancing pressure, and providing protection of the corneal endothelial cells during surgery.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F151049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Intravitreous injection: Diffusion occurs slowly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: By Canal of Schlemm",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Arshinoff SA and Jafari M, &ldquo;Laboratory Science: New Classification of Ophthalmic Viscosurgical Devices-2005&rdquo;",
"      <i>",
"       J Cataract Refract Surg",
"      </i>",
"      , 2005, 31(11):2167-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/47/36594/abstract-text/16412934/pubmed\" id=\"16412934\" target=\"_blank\">",
"        16412934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9235 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-95F309B6B5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_47_36594=[""].join("\n");
var outline_f35_47_36594=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151056\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151063\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151057\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151058\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151045\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151033\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151047\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151046\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151061\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151050\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151037\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300054\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222988\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323066\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390210\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151036\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151049\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9235\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9235|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/10/20643?source=related_link\">",
"      Chondroitin sulfate-sodium hyaluronate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_47_36595="Prilocaine and epinephrine: Patient drug information";
var content_f35_47_36595=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Prilocaine and epinephrine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F213770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Citanest&reg; Forte Dental",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F213771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Citanest&reg; Forte",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691288",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used before dental care to numb the area.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702791",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to prilocaine, epinephrine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfite allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696752",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not eat while your mouth feels numb. You may bite your tongue.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weakness, numbness, or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor will give this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696006",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10025804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11570 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-259ED97FEC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_47_36595=[""].join("\n");
var outline_f35_47_36595=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213770\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213771\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025801\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025800\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025805\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025806\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025808\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025803\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025804\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025809\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025810\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_47_36596="Marginal placenta previa";
var content_f35_47_36596=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55703&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55703&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Marginal placenta previa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 338px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transvaginal study shows a posterior placenta with the tip of the placenta on the internal os (arrow). The placenta is adjacent to the internal os, but does not cover it.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_47_36596=[""].join("\n");
var outline_f35_47_36596=null;
var title_f35_47_36597="Lichen planus penis";
var content_f35_47_36597=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F60985&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F60985&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Penile lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 269px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lichen planus. Wickham's striae are visible.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_47_36597=[""].join("\n");
var outline_f35_47_36597=null;
var title_f35_47_36598="Primary neurulation";
var content_f35_47_36598=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72061&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72061&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 628px\">",
"   <div class=\"ttl\">",
"    Schematic representation of primary neurulation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 608px; height: 446px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The central nervous system initially appears as a plate of thickened ectoderm called the neural plate at the beginning of the third week of embryonic life (panel 2). The lateral edges of the neural plate become elevated to form the neural folds, around the neural groove (panel 3). These folds subsequently fuse to form the neural tube (panel 4).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Dr. Martin Ronan, Medical Sciences, Indiana University. Copyright &copy; 2009 Martin Ronan. Accessed (Jan. 27, 2009) at: file://www.indiana.edu/~phys215/lecture/lecnotes/chap8N.html",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_47_36598=[""].join("\n");
var outline_f35_47_36598=null;
var title_f35_47_36599="Sodium phosphate: Pediatric drug information";
var content_f35_47_36599=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sodium phosphate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?5/22/5480?source=see_link\">",
"    see \"Sodium phosphate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/15/19702?source=see_link\">",
"    see \"Sodium phosphate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F7688983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F221976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Fleet&reg; Enema Extra&reg; [OTC];",
"     </li>",
"     <li>",
"      Fleet&reg; Enema [OTC];",
"     </li>",
"     <li>",
"      Fleet&reg; Pedia-Lax&trade; Enema [OTC];",
"     </li>",
"     <li>",
"      LaCrosse Complete [OTC];",
"     </li>",
"     <li>",
"      OsmoPrep&reg;;",
"     </li>",
"     <li>",
"      Visicol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F221977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Fleet Enema&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1036259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Electrolyte Supplement, Oral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Electrolyte Supplement, Parenteral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Laxative, Saline",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Sodium Salt",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11445047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Consider the contribution of sodium when determining the appropriate phosphate replacement.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Phosphorus Estimated Average Requirement (EAR): Dietary Intake Reference (DIR) (1997 National Academy of Science Recommendations) (",
"     <b>",
"      Note:",
"     </b>",
"     DIR is under review as of March 2009): Oral: 3.2 mmol/day (adequate intake)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Maintenance:",
"     </b>",
"     I.V.: 0.8-1.5 mmol/kg/day",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1036284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?5/22/5480?source=see_link\">",
"      see \"Sodium phosphate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Consider the contribution of sodium when determining the appropriate phosphate replacement.",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Phosphorus: Oral: See table.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Phosphorus &minus; Recommended Daily Allowance (RDA) and Estimated Average Requirement (EAR)",
"     </caption>",
"     <col width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"120\">",
"     </col>",
"     <col align=\"center\" width=\"120\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Age",
"        </p>",
"       </th>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         RDA",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mmol/day)",
"        </p>",
"       </th>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         EAR",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mmol/day)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"top\">",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          A",
"         </sup>",
"         Adequate intake (AI)",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         1-6 mo",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &minus;",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3.2",
"         <sup>",
"          A",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         7-12 mo",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &minus;",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8.9",
"         <sup>",
"          A",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         1-3 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         14.8",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         12.3",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         4-8 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         16.1",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         13.1",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         9-18 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         40.3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         34",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         19-30 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         22.6",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         18.7",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Hypophosphatemia:",
"     </b>",
"     Hypophosphatemia does not necessarily equate with phosphate depletion. Hypophosphatemia may occur in the presence of low, normal, or high total body phosphate and conversely, phosphate depletion may exist with normal, low, or elevated levels of serum phosphate (Gaasbeek, 2005). It is difficult to provide concrete guidelines for the treatment of severe hypophosphatemia because the extent of total body deficits and response to therapy are difficult to predict. Aggressive doses of phosphate may result in a transient serum elevation followed by redistribution into intracellular compartments or bone tissue. Various regimens for replacement of phosphate in adults have been studied. The regimens below have only been studied in adult patients; however, many institutions have used them in children safely and successfully.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     I.V. doses may be incorporated into the patient's maintenance I.V. fluids; intermittent I.V. infusion should be reserved for severe depletion situations.",
"     <b>",
"      Note:",
"     </b>",
"     Doses listed as mmol of",
"     <b>",
"      phosphate",
"     </b>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Intermittent I.V. infusion: It is recommended that repletion of severe hypophosphatemia be done I.V. because large doses of oral phosphate may cause diarrhea and intestinal absorption may be unreliable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children and Adults:",
"     <b>",
"      Note:",
"     </b>",
"     There are no prospective studies of parenteral phosphate replacement in children. The following weight-based guidelines for adult dosing may be cautiously employed in pediatric patients. Guidelines differ based on degree of illness, use of TPN, and severity of hypophosphatemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:2em;text-align:justify;\">",
"     General replacement guidelines (Lentz, 1978):",
"     <b>",
"      Note:",
"     </b>",
"     The initial dose may be increased by 25% to 50% if the patient is symptomatic secondary to hypophosphatemia and lowered by 25% to 50% if the patient is hypercalcemic.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Low dose: 0.08 mmol/kg over 6 hours; use if losses are recent and uncomplicated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Intermediate dose: 0.16-0.24 mmol/kg over 4-6 hours; use if serum phosphorus level 0.5-1 mg/dL (0.16-0.32 mmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     High dose: 0.36 mmol/kg over 6 hours; use if serum phosphorus &lt;0.5 mg/dL (&lt;0.16 mmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:2em;text-align:justify;\">",
"     Patients receiving TPN (Clark, 1995):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Low dose: 0.16 mmol/kg over 4-6 hours; use if serum phosphorus level 2.3-3 mg/dL (0.73- 0.96 mmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Intermediate dose: 0.32 mmol/kg over 4-6 hours; use if serum phosphorus level 1.6-2.2 mg/dL (0.51-0.72 mmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     High dose: 0.64 mmol/kg over 8-12 hours; use if serum phosphorus &lt;1.5 mg/dL (&lt; 0.5 mmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:2em;text-align:justify;\">",
"     Critically ill adult trauma patients receiving TPN (Brown, 2006):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Low dose: 0.32 mmol/kg over 4-6 hours; use if serum phosphorus level 2.3-3 mg/dL (0.73-0.96 mmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Intermediate dose: 0.64 mmol/kg over 4-6 hours; use if serum phosphorus level 1.6-2.2 mg/dL (0.51-0.72 mmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     High dose: 1 mmol/kg over 8-12 hours; use if serum phosphorus &lt;1.5 mg/dL (&lt; 0.5 mmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:2em;text-align:justify;\">",
"     Alternative method in critically ill patients (Kingston, 1985):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Low dose: 0.25 mmol/kg over 4 hours; use if serum phosphorus level 0.5-1 mg/dL (0.16-0.32 mmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Moderate dose: 0.5 mmol/kg over 4 hours; use if serum phosphorus level &lt;0.5 mg/dL (&lt;0.16 mmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">",
"     Adults: 15 mmol/dose over 2 hours; use if serum phosphorus &lt;2 mg/dL (0.65 mmol/L); may repeat in 6- to 8-hour intervals if repeat serum phosphorus (at least 6 hours postdose) &lt;2 mg/dL (0.65 mmol/L); not to exceed 45 mmol/24 hours (Rosen, 1995)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Maintenance:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants and Children &lt;25 kg: 0.5-1.5 mmol/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 25-45 kg: 0.5-1 mmol/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: 2-3 mmol/kg/day in divided doses (including dietary intake)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 50-70 mmol/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 50-150 mmol/day in divided doses (including dietary intake)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Constipation:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Oral, solution (Monobasic sodium phosphate monohydrate 2.4 g and dibasic sodium phosphate heptahydrate 0.9 g per 5 mL):",
"     <b>",
"      Note:",
"     </b>",
"     Must be diluted in a full glass of water:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Children 5-9 years: 7.5 mL as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Children 10-11 years: 15 mL as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Children &ge;12 years and Adults: 15-45 mL as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Rectal: Fleet&reg; Enema:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Children 2-4 years: One half contents of one 2.25 ounce pediatric enema as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Children 5-11 years: Contents of one 2.25 ounce pediatric enema as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Children &ge;12 years and Adults: Contents of one 4.5 ounce enema as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Evacuation of colon prior to colonoscopy:",
"     </b>",
"     Adults &ge;18 years: Administer each 4 tablets with 8 ounces of water:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     OsmoPrep&trade;: Prior to colonoscopy per manufacturer: The night before the procedure: 4 tablets every 15 minutes until a total dose of 20 tablets; repeat starting 3-5 hours before the procedure with 4 tablets every 15 minutes for a total of 12 tablets",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Visicol&reg;: Prior to colonoscopy per manufacturer: The night before the procedure: 4 tablets every 15 minutes until a total dose of 20 tablets; repeat 3-5 hours before the procedure with 4 tablets every 15 minutes until a total dose of 40 tablets has been administered",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F221959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution [concentrate; preservative free]: Phosphorus 3 mmol and sodium 4 mEq per 1 mL (5 mL, 15 mL, 50 mL) [equivalent to phosphorus 93 mg and sodium 92 mg per 1 mL; source of electrolytes: monobasic and dibasic sodium phosphate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: Monobasic sodium phosphate monohydrate 2.4 g and dibasic sodium phosphate heptahydrate 0.9 g per 5 mL (45 mL) [sugar free; contains sodium 556 mg/5 mL, sodium benzoate; ginger-lemon flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, rectal [enema]: Monobasic sodium phosphate monohydrate 19 g and dibasic sodium phosphate heptahydrate 7 g per 118 mL delivered dose (133 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fleet&reg; Enema: Monobasic sodium phosphate monohydrate 19 g and dibasic sodium phosphate heptahydrate 7 g per 118 mL delivered dose (133 mL) [contains sodium 4.4 g/118 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fleet&reg; Enema Extra&reg;: Monobasic sodium phosphate monohydrate 19 g and dibasic sodium phosphate heptahydrate 7 g per 197 mL delivered dose (230 mL) [contains sodium 4.4 g/197 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fleet&reg; Pedia-Lax&trade; Enema: Monobasic sodium phosphate monohydrate 9.5 g and dibasic sodium phosphate heptahydrate 3.5 g per 59 mL delivered dose (66 mL) [contains sodium 2.2 g/59 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LaCrosse Complete: Monobasic sodium phosphate monohydrate 19 g and dibasic sodium phosphate heptahydrate 7 g per 118 mL delivered dose (133 mL) [contains sodium 4.4 g/118 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral [scored]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     OsmoPrep&reg;, Visicol&reg;: Monobasic sodium phosphate monohydrate 1.102 g and dibasic sodium phosphate anhydrous 0.398 g [sodium phosphate 1.5 g per tablet; gluten free]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F221943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Enema, injection, oral solution",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     OsmoPrep&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM135936.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM135936.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Visicol&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM134684.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM134684.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1036290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Administer with food to reduce the risk of diarrhea (unless using for bowel preparation); maintain adequate fluid intake; dilute oral solution in 8 ounces of cool water, follow with an additional 8 ounces of water. Products used as preparation for colonoscopy (OsmoPrep&trade;, Visicol&reg;) should be administered with at least 8 ounces water for each dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: For intermittent I.V. infusion: Peripheral line: Dilute to a maximum concentration of 0.05 mmol/mL; Central line: Dilute to a maximum concentration of 0.12 mmol/mL (maximum concentrations were determined with consideration for maximum sodium concentration); maximum rate of infusion: 0.06 mmol/kg/hour; do",
"     <b>",
"      not",
"     </b>",
"     infuse with calcium-containing I.V. fluids",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F221993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Doripenem, micafungin, telavancin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amiodarone.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ciprofloxacin, TPN.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1036276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature; phosphate salts may precipitate when mixed with calcium salts; solubility is improved in parenteral nutrition solutions which contain amino acids; check with a pharmacist to determine compatibility",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1036260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Treatment and prevention of hypophosphatemia; short-term treatment of constipation (oral/rectal); evacuation of the colon for rectal and bowel exams; source of phosphate in large volume I.V. fluids",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2931717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Visicol&reg; may be confused with Asacol&reg;, VESIcare&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Enemas and oral solution are available in pediatric and adult sizes; prescribe by &ldquo;volume&rdquo; not by &ldquo;bottle.&rdquo;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Because inorganic phosphate exists as monobasic and dibasic anions, with the mixture of valences dependent on pH, ordering by mEq amounts is unreliable and may lead to large dosing errors. In addition, I.V. phosphate is available in the sodium and potassium salt; therefore, the content of these cations must be considered when ordering phosphate. The most reliable method of ordering I.V. phosphate is by millimoles, then specifying the potassium or sodium salt.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F221992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, bloating, mucosal bleeding, nausea, superficial mucosal ulcerations, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypernatremia, hyperphosphatemia, hypocalcemia (on colonoscopy day), hypokalemia (on colonoscopy day), hypophosphatemia (2-3 days postcolonoscopy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Acute phosphate nephropathy, anaphylaxis, bronchospasm, calcium nephrolithiasis, cardiac arrhythmia, dehydration, dysphagia, dyspnea, facial edema, increased blood urea nitrogen, increased serum creatinine, ischemic colitis, lip edema, paresthesia, pharyngeal edema, pruritus, rectal bleeding, renal failure, renal insufficiency, renal tubular necrosis, seizure, skin rash, tightness in throat, tongue edema, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1036264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to phosphate (salts) or any component; hyperphosphatemia, hypocalcemia, hypomagnesemia, hypernatremia, severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute), severe tissue trauma, heat cramps, abdominal pain (rectal forms), fecal impaction (rectal forms)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F3426449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with considerable caution in patients with renal impairment, CHF, unstable angina, gastric retention, ileus, acute bowel obstruction, pseudo-obstruction of the bowel, severe chronic constipation, bowel perforation, acute colitis, toxic megacolon, gastric bypass or stapling surgery, hypomotility syndrome, and ascites; use with caution in patients with adrenal insufficiency, chronic inflammatory bowel disease, and cirrhosis. Some products contain phenylalanine; use with caution in patients with phenylketonuria.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1036265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administration of sodium phosphate products (OsmoPrep&trade;, Visicol&reg;, &gt;45 mL/day oral sodium phosphate solution) as a bowel preparation in adults has been associated with significant fluid shifts, severe electrolyte abnormalities, and cardiac arrhythmias resulting in symptomatic dehydration, renal failure, metabolic acidosis, tetany, and death; fatalities have been observed in patients with renal insufficiency, bowel perforation, and in patients who misused or overdosed sodium phosphate products. Consider obtaining baseline and post-treatment electrolytes particularly in patients who may be at increased risk for serious adverse events, including patients with history of acute phosphate nephropathy, known or suspected electrolyte disorders, seizures, arrhythmias, cardiomyopathy, prolonged QT, or recent history of MI. Patients should be adequately hydrated before, during, and after use. Hypovolemia, kidney disease, bowel obstruction, acute colitis, increased age, and medications affecting renal perfusion or function such as diuretics, ACE inhibitors, ARBs, and NSAIDs have been associated with the development of renal failure and acute phosphate nephropathy in patients receiving sodium phosphate for colon cleansing; some cases have resulted in permanent renal impairment (some requiring dialysis). Acute phosphate nephropathy has also been reported in patients without apparent risk factors. Correct dehydration and avoid exceeding the maximum recommended doses and concurrent use of other laxatives containing sodium phosphate. Oral solution contains sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; use oral solution containing sodium benzoate with caution in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F221952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with ACEIs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with ARBs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Phosphate Supplements.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: May enhance the hypocalcemic effect of Phosphate Supplements.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May decrease the absorption of Phosphate Supplements.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diuretics: May enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: May decrease the absorption of Phosphate Supplements. Management: Administer oral phosphate supplements at least 1 hour before, or 2 hours after, oral iron salt administration.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May decrease the serum concentration of Phosphate Supplements. Management: Administer oral phosphate supplements at least 1 hour before, or 2 hours after, oral magnesium salt administration.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Phosphate Supplements. Management: Administer oral phosphate supplements at least 1 hour before, or 2 hours after, administration of an iron-containing multivitamin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: Sodium Phosphates may enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May decrease the absorption of Phosphate Supplements.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure and/or loss of consciousness may be increased in patients with significant sodium phosphate induced fluid/electrolyte abnormalities.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F3426450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Avoid giving with oxalate (ie, berries, nuts, chocolate, beans, celery, tomatoes) or phytate-containing foods (ie, bran, whole wheat).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F221954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F221968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted with these products. Use with caution in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1036293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Serum sodium, calcium, phosphorus, renal function, reflexes, stool output (laxative use)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F3426716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     There is a diurnal variation with the nadir at 1100, plateau at 1600, and peak in the early evening (Gaasbeek, 2005); 1 mmol/L phosphate = 3.1 mg/dL phosphorus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Newborns: 4.2-9 mg/dL phosphorus (1.36-2.91 mmol/L phosphate)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     6 weeks to 18 months: 3.8-6.7 mg/dL phosphorus (1.23-2.16 mmol/L phosphate)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     18 months to 3 years: 2.9-5.9 mg/dL phosphorus (0.94-1.91 mmol/L phosphate)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     3-15 years: 3.6-5.6 mg/dL phosphorus (1.16-1.81 mmol/L phosphate)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;15 years: 2.5-5 mg/dL phosphorus (0.81-1.62 mmol/L phosphate)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Hypophosphatemia:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Moderate: 1-2 mg/dL phosphorus (0.32-0.65 mmol/L phosphate)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Severe: &lt;1 mg/dL phosphorus (&lt;0.32 mmol/L phosphate)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1036280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Phosphorus is an essential mineral that is usually found in nature combined with oxygen as phosphate.  It participates in bone deposition, calcium metabolism, as part of molecules that regulate many coenzymes, steps in the clotting cascade, and functions of the immune system.  It is a component of the lipid  bilayer of cell membranes in the form of phospholipids and of other intracellular compounds like nucleic acids and nucleoproteins.  It acts as a buffer for the maintenance of plasma and urinary pH. When administered orally or rectally as a laxative, it exerts osmotic effect in the small intestine by drawing water into the lumen of the gut, producing distension, promoting peristalsis, and evacuation of the bowel.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F3426451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action (catharsis):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: 3-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rectal: 2-5 minutes",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1036281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: 1% to 20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Oral forms excreted in feces; I.V. forms are excreted in the urine with over 80% to 90% of dose reabsorbed by the kidney",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F3426717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Each mmol of phosphate contains 31 mg elemental phosphorus; 1 mmol/L phosphate = 3.1 mg/dL phosphorus; cow's milk is a good source of phosphate with 1 mg elemental (0.032 mmol) elemental phosphate per mL",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     With orders for I.V. phosphate, there is considerable confusion associated with the use of millimoles (mmol) versus milliequivalents (mEq) to express the phosphate requirement. Because inorganic phosphate exists as monobasic and dibasic anions, with the mixture of valences dependent on pH, ordering by mEq amounts is unreliable and may lead to large dosing errors. In addition, I.V. phosphate is available in the sodium and potassium salt; therefore, the content of these cations must be considered when ordering phosphate. The most reliable method of ordering I.V. phosphate is by millimoles, then specifying the potassium or sodium salt.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Brown KA, Dickerson RN, Morgan LM, et al, &ldquo;A New Graduated Dosing Regimen for Phosphorus Replacement in Patients Receiving Nutrition Support,&rdquo;",
"      <i>",
"       JPEN",
"      </i>",
"      , 2006, 30(3):209-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/47/36599/abstract-text/ 16639067 /pubmed\" id=\" 16639067 \" target=\"_blank\">",
"        16639067",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clark CL, Sacks GS, Dickerson RN, et al, &ldquo;Treatment of Hypophosphatemia in Patients Receiving Specialized Nutrition Support Using a Graduated Dosing Scheme: Results From a Prospective Clinical Trial,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1995, 23(9):1504-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/47/36599/abstract-text/7664552/pubmed\" id=\"7664552\" target=\"_blank\">",
"        7664552",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine,&rdquo; National Academy of Sciences, Washington, DC: National Academy Press, 1997.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gaasbeek A and Meinders AE, &ldquo;Hypophosphatemia: An Update on Its Etiology and Treatment&rdquo;,",
"      <i>",
"       Am J Med",
"      </i>",
"      , 2005, 118(10):1094-101.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/47/36599/abstract-text/16194637/pubmed\" id=\"16194637\" target=\"_blank\">",
"        16194637",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kingston M and Al-Siba'i MB, \"Treatment of Severe Hypophosphatemia,\"",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1985, 13(1):16-8",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/47/36599/abstract-text/3965243/pubmed\" id=\"3965243\" target=\"_blank\">",
"        3965243",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lentz RD, Brown BM, and Kjellstrand CM, &ldquo;Treatment of Severe Hypophosphatemia,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1978, 89(6):941-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/47/36599/abstract-text/102230 /pubmed\" id=\"102230 \" target=\"_blank\">",
"        102230",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lloyd CW and Johnson CE, &ldquo;Management of Hypophosphatemia,&rdquo;",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1988, 7(2):123-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/47/36599/abstract-text/3280219/pubmed\" id=\"3280219\" target=\"_blank\">",
"        3280219",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosen GH, Boullata JI, O'Rangers EA, et al, &ldquo;Intravenous Phosphate Repletion Regimen for Critically Ill Patients With Moderate Hypophosphatemia,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1995, 23(7):1204-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/47/36599/abstract-text/7600828/pubmed\" id=\"7600828\" target=\"_blank\">",
"        7600828",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12987 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-8913731101-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_47_36599=[""].join("\n");
var outline_f35_47_36599=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7688983\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221976\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221977\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1036259\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11445047\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1036284\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221959\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221943\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874991\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1036290\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221993\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1036276\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1036260\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2931717\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221992\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1036264\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3426449\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1036265\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300067\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221952\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3426450\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221954\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221968\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1036293\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3426716\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1036280\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3426451\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1036281\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3426717\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12987\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12987|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?5/22/5480?source=related_link\">",
"      Sodium phosphate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/15/19702?source=related_link\">",
"      Sodium phosphate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_47_36600="Female orgasmic disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis";
var content_f35_47_36600=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Female orgasmic disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/47/36600/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/47/36600/contributors\">",
"     Andrea Bradford, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/47/36600/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/47/36600/contributors\">",
"     Robert Segraves, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/47/36600/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/47/36600/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/47/36600/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H7344372\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Female orgasmic disorder is characterized by a persistent or recurrent delay in or absence of orgasm following sexual arousal and adequate sexual stimulation. To diagnose female orgasmic disorder, the symptoms must cause marked distress or interpersonal difficulty [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/1\">",
"     1",
"    </a>",
"    ]. Treatment for female orgasmic disorder consists principally of psychosocial interventions, though clinical trials of their efficacy are limited.",
"   </p>",
"   <p>",
"    This topic discusses the epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis of female orgasmic disorder. The treatment of female orgasmic disorder is discussed separately. The assessment of patients with sexual dysfunction is also discussed separately. The epidemiology, risk factors, evaluation, and an overview of treatment of women with sexual dysfunction are also discussed separately. The prevalence and management of sexual dysfunction due to serotonergic antidepressants are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/48/2824?source=see_link\">",
"     \"Treatment of female orgasmic disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/57/42904?source=see_link\">",
"     \"The sexual history and approach to the patient with sexual dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25258?source=see_link\">",
"     \"Sexual dysfunction in women: Epidemiology, risk factors, and evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/10/34985?source=see_link\">",
"     \"Sexual dysfunction in women: Management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2039?source=see_link&amp;anchor=H2#H2\">",
"     \"Sexual dysfunction associated with selective serotonin reuptake inhibitor (SSRI) antidepressants\", section on 'Management of sexual dysfunction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H457298724\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Female orgasmic disorder may be lifelong or acquired, generalized (occurring in all situations) or situational (occurring in select situations). An example of the situational type of the disorder is a woman who has orgasms through masturbation but not during partnered sexual activity",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H457298731\">",
"    <span class=\"h2\">",
"     Primary female orgasmic disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with primary female orgasmic disorder have not previously experienced orgasm in any situation. Other terms used synonymously include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      &ldquo;Lifelong generalized female orgasmic disorder&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;Primary anorgasmia&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;Preorgasmic&rdquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H457298738\">",
"    <span class=\"h2\">",
"     Secondary female orgasmic disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with secondary female orgasmic disorder have previously been orgasmic but present with current orgasmic dysfunction. As examples, this category would include women who were once orgasmic but not any longer (generalized) as well as women who are orgasmic through masturbation but not partnered sexual activity (situational).",
"   </p>",
"   <p>",
"    Other terms used synonymously include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      &ldquo;Situational orgasmic disorder&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;Acquired orgasmic disorder&rdquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7344379\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic studies have found the estimated prevalence of orgasmic dysfunction to vary internationally from approximately 20 to 40 percent. Female orgasmic disorder has a lower prevalence than these estimates, because diagnostic criteria for female orgasmic disorder require that the symptoms are distressing or bothersome to the respondent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12710883\">",
"     'Diagnostic criteria'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Surveys conducted in the US, the United Kingdom, and Australia have estimated that 21 to 29 percent of women report problems with attaining orgasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/4-8\">",
"     4-8",
"    </a>",
"    ]. As an example, a nationally representative survey of over 25,000 adult women in the US found that approximately 21 percent reported problems with attaining orgasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from a study of 40- to 80-year-old adults in 29 countries found somewhat higher prevalences of problems with orgasm among women in Asian countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/11\">",
"     11",
"    </a>",
"    ], although comparisons across studies are limited by the use of different assessment methods. Occasional to frequent anorgasmia was reported by: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      32.3 percent of women surveyed in China, Hong Kong, Japan, Korea, and Taiwan",
"     </li>",
"     <li>",
"      41.2 percent of women surveyed in Indonesia, Malaysia, Philippines, Singapore, and Thailand",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Only a subgroup of these samples may have met criteria for female orgasmic disorder. A study of 500 US women using a more detailed instrument found that only 4.7 percent of respondents endorsed both problems with orgasm and high levels of associated distress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/12\">",
"     12",
"    </a>",
"    ]. A similarly designed study of 356 Australian women concluded that 8 percent of women endorsed problems with orgasm and related personal distress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bisexual and lesbian women are not well represented in epidemiological studies of sexual dysfunction, but smaller studies have found rates of orgasm problems that are consistent with rates in the broader population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/5,14\">",
"     5,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4531689\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Demographic risk factors for orgasm problems in the general population include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/11,15-17\">",
"     11,15-17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lower educational attainment",
"     </li>",
"     <li>",
"      Lower income",
"     </li>",
"     <li>",
"      Poorer health status",
"     </li>",
"     <li>",
"      Depression and other mental health disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Population-based studies do not show a consistent link between age and problems with orgasm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4531773\">",
"    <span class=\"h2\">",
"     Comorbid disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few rigorous studies of comorbidity of female orgasmic disorder specifically, although several studies have examined associations between subjective difficulty with orgasm and other psychiatric conditions.",
"   </p>",
"   <p>",
"    Women with depression are two-to-four times more likely than non-depressed women to report problems in reaching orgasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/4,18\">",
"     4,18",
"    </a>",
"    ]. This association may be weaker outside the US and UK [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/11\">",
"     11",
"    </a>",
"    ]. In a survey of a nationally representative household survey in the US, 55 percent of adult women who reported a distressing problem with orgasm also endorsed one or more key symptoms of depression. Similar percentages of depressed women reported problems with low sexual desire and sexual arousal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/9\">",
"     9",
"    </a>",
"    ], suggesting a generalized effect of depression on sexual function in women.",
"   </p>",
"   <p>",
"    Clinically significant anxiety symptoms are associated with a twofold risk of problems with orgasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/18\">",
"     18",
"    </a>",
"    ]. Obsessive-compulsive disorder may specifically confer risk for problems with orgasm, which may reflect difficulties with sexual expression in general [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7344480\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of female orgasmic disorder is best understood in the context of women&rsquo;s normal orgasmic function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7344386\">",
"    <span class=\"h2\">",
"     Normal functioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physiologic and subjective components of women&rsquo;s orgasm are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/57/42904?source=see_link&amp;anchor=H3#H3\">",
"     \"The sexual history and approach to the patient with sexual dysfunction\", section on 'Normal sexual function'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25258?source=see_link&amp;anchor=H2#H2\">",
"     \"Sexual dysfunction in women: Epidemiology, risk factors, and evaluation\", section on 'Female sexual response cycle'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women vary in the intensity, type, and duration of stimulation required for orgasm. Most women require some degree of clitoral stimulation to experience orgasm. Indirect stimulation of the clitoris through vaginal intercourse may be sufficient to trigger orgasm in the majority of women, at least part of the time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/17\">",
"     17",
"    </a>",
"    ]; whereas, others may respond more readily and reliably to direct clitoral stimulation. Stimulation of other erotically sensitive areas (eg, breast or nipple stimulation) may trigger orgasm as well. Some women with complete spinal cord injury maintain the ability to experience orgasm through vaginal-cervical stimulation, a process that appears to be vagally mediated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. As examples, orgasms can occur in women during sleep [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/22,23\">",
"     22,23",
"    </a>",
"    ], and there are isolated reports of women who are able to experience orgasm through fantasy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anatomic differences among women may explain some variation in the ease with which women may experience orgasm solely through vaginal intercourse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. The inability to do so is not a disorder per se, but rather a typical (and sometimes modifiable) variant of sexual response.",
"   </p>",
"   <p>",
"    Recent data from population-based twin studies suggest that heritable factors may account for over 30 percent of variance in orgasmic frequency during intercourse and at least 45 percent of variance in orgasmic frequency with masturbation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7344393\">",
"    <span class=\"h2\">",
"     Psychological and cultural factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Problems with orgasm in women are multifactorial and may be related to a variety of inhibitory psychosocial factors at the level of the individual, couple,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sociocultural context. While some of these factors are modifiable, others may represent more stable traits (eg, a general tendency toward behavioral inhibition such as introversion, or a lower propensity for sexual excitement).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12710668\">",
"    <span class=\"h3\">",
"     Intrapsychic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;While early development of treatments for sexual dysfunction were based on the concept of &ldquo;sexual anxiety&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/30,31\">",
"     30,31",
"    </a>",
"    ], the general concept of inhibition may apply more broadly to the understanding of female orgasmic disorder.",
"   </p>",
"   <p>",
"    The Dual Control Model proposes that a combination of excitatory and inhibitory processes contribute to sexual response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/32\">",
"     32",
"    </a>",
"    ]. The model posits that individuals vary in their propensity for sexual excitation and inhibition based on a variety of factors including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Genetics",
"     </li>",
"     <li>",
"      Prior experiences",
"     </li>",
"     <li>",
"      Sociocultural context",
"     </li>",
"     <li>",
"      Motivational factors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Research suggests that inhibitory factors associated with orgasmic difficulty include worry about one&rsquo;s own sexual function and the tendency to be easily distracted or interrupted from sexual arousal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/33\">",
"     33",
"    </a>",
"    ]. However, it is unclear whether these factors cause or are caused by orgasmic dysfunction. Evidence suggests that individuals who report being more easily sexually aroused are less likely to experience orgasmic dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sexual inhibition contributing to anorgasmia may be a manifestation of personality traits. A population-based study suggested that infrequent coital orgasm is associated with personality traits of introversion, emotional instability, and less openness to new experiences, whereas agreeableness and conscientiousness appear unrelated to orgasmic frequency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12710675\">",
"    <span class=\"h3\">",
"     Relationship factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies suggest that members of heterosexual couples with an anorgasmic female partner exhibit more difficulty communicating about sexual topics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. One study found that women who endorsed a need for sex to occur within a trusting or emotionally &ldquo;safe&rdquo; relationship context were less likely to experience problems with orgasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/33\">",
"     33",
"    </a>",
"    ]. Women who have concerns or doubts about the future of their intimate relationships are more likely to report problems with orgasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/11\">",
"     11",
"    </a>",
"    ]. In shared sexual activities, one partner&rsquo;s sexual function and willingness to engage in mutually pleasurable activities influence orgasmic function in the other partner.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12710687\">",
"    <span class=\"h3\">",
"     Sociocultural factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sociocultural factors may influence a woman&rsquo;s comfort with sexual expression and experience of orgasm. Cultures vary with respect to their recognition of, and emphasis on, female sexual pleasure; these factors may influence the ease with which women attain orgasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/37\">",
"     37",
"    </a>",
"    ]. Sexual guilt and endorsement of common sexual myths are associated with orgasm problems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/34\">",
"     34",
"    </a>",
"    ]. Pinpointing the origins of negative sexual attitudes and myths, however, is not straightforward. Although certain forms of religious expression influence sexual attitudes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/38\">",
"     38",
"    </a>",
"    ], religiosity per se does not necessarily hinder orgasmic function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7344407\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although female orgasmic disorder may manifest as a complete absence of orgasm, some women with acquired female orgasmic disorder report delayed orgasm (ie, requiring longer",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    more intense stimulation to reach orgasm) or a less intense experience of orgasm. Women may also report a sense of impending orgasm that does not reach a peak or resolution despite continued stimulation, sometimes resulting in a feeling of sexual frustration or unresolved genital tension.",
"   </p>",
"   <p>",
"    Orgasmic dysfunction caused by medical illness or drug treatment is usually experienced globally, that is, in both partnered and masturbatory activity, whereas acquired situational female orgasmic disorder is more likely to manifest only in partnered sexual activity.",
"   </p>",
"   <p>",
"    A clinical presentation that may initially be described as lifelong orgasmic dysfunction is a woman with an intact orgasmic response who does not recognize it as such due to inaccurate expectations of orgasm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7344414\">",
"    <span class=\"h1\">",
"     COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of female orgasmic disorder is heterogeneous due to variation in its etiology. Studies have not been consistent in the methods used to measure the duration of orgasmic dysfunction, but some data are available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      3.7 percent of women in a large UK sample reported inability to orgasm lasting six months or longer",
"     </li>",
"     <li>",
"      14.4 percent reported an orgasm problem lasting one month or longer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In young women and in women with limited sexual experience, the course of lifelong, global female orgasmic disorder is difficult to distinguish from normal sexual development. A period of sustained sexual activity is generally necessary in order to establish whether the problem is persistent or recurrent, although a pattern of orgasm difficulty with masturbation could meet this criterion. Once manifest, the disorder is likely to persist if precipitating factors (eg, stress, relationship conflict, medication use) do not resolve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7344421\">",
"    <span class=\"h1\">",
"     ASSESSMENT AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment and diagnosis of female orgasmic disorder is based on self-reported symptoms, usually during the course of a clinical interview. The clinician should evaluate the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A general description of how the problem is experienced (eg, delayed, absent,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      weak orgasm). Women with primary anorgasmia may express uncertainty about what orgasm feels like.",
"     </li>",
"     <li>",
"      Frequency of symptoms (ie, the proportion of sexual encounters in which there is a problem with orgasm)",
"     </li>",
"     <li>",
"      Situational specificity of the problem (ie, whether the problem is global or specific to certain sexual activities, partners, or other situational factors)",
"     </li>",
"     <li>",
"      The onset and duration of symptoms, including any change over time",
"     </li>",
"     <li>",
"      Experiences of sexual",
"      <span class=\"nowrap\">",
"       interest/excitement",
"      </span>",
"      and perception of genital arousal during sexual encounters",
"     </li>",
"     <li>",
"      Presence or absence of difficulties with orgasm during masturbation",
"     </li>",
"     <li>",
"      Presence of conflict, distrust, or instability in the sexual relationship",
"     </li>",
"     <li>",
"      Prior negative experiences of sexuality",
"     </li>",
"     <li>",
"      Prior treatment experiences",
"     </li>",
"     <li>",
"      Symptoms of other psychiatric disorders",
"     </li>",
"     <li>",
"      Medical history including current use of medications",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It can be difficult to describe or assess the intensity of arousal. Asking the woman to what extent she feels &ldquo;excited&rdquo; or &ldquo;turned on&rdquo; during sexual encounters can help establish her subjective perception of sexual arousal. It can be helpful for the clinician to inquire about the patient's experience of physical indicators of sexual arousal during sexual stimulation, such as genital warmth, tension, pulsing, and lubrication. If the woman appears to experience little or no sexual arousal with most sexual encounters, the diagnoses of female sexual arousal disorder",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypoactive sexual desire disorder should be considered.",
"   </p>",
"   <p>",
"    The clinician should assess whether the patient&rsquo;s symptoms have been life-long or acquired. When acquired female orgasmic disorder is suspected, it is important to compare feelings of arousal to the previous state of functioning.",
"   </p>",
"   <p>",
"    The clinician should investigate whether the patient&rsquo;s symptoms are situational or generalized. It is common for women to report experiencing orgasm through self-stimulation but not during partnered sexual activity. This alone does not necessarily establish the presence of situational female orgasmic disorder, since partnered sexual activity may not be sufficiently arousing, or the problem may not be sufficient to cause distress in this context. If orgasm problems are limited to one particular partner but not past partners, careful assessment may reveal interpersonal problems or concerns about the pattern of sexual activity in the relationship. Alternatively, the partner may lack sexual knowledge and skills. The clinician should be sensitive to the possibility that a patient may find it less threatening to take on the label of &ldquo;dysfunctional&rdquo; than to describe problems with the partner or the relationship",
"   </p>",
"   <p>",
"    Anxiety or inhibition related to sexuality can be assessed by inquiring about the frequency of self-monitoring during sexual activity, the woman&rsquo;s level of comfort in discussing sexual topics with her partner, and her perception of her own body, especially her genitals. Observing the woman&rsquo;s speech and behavior (eg, marked avoidance of language referring to genitals or sexual behaviors) may also provide evidence of general discomfort with sexuality. Further assessment may include queries about sexual mores and values in the woman&rsquo;s family of origin, which may reveal negative attitudes or a lack of knowledge about sexuality.",
"   </p>",
"   <p>",
"    Women in intimate relationships sometimes bring their partners to a clinical assessment. Interviewing the couple jointly can yield valuable data about how the partners communicate, solve problems together, and show affection. The woman should ideally be interviewed alone at some point during the assessment so that private thoughts and feelings can be shared candidly. As an example, the woman may feel uncomfortable talking about her lack of sexual knowledge in the presence of her partner, or she may have difficulty voicing her sexual frustrations and wishes. Some material may be &ldquo;taboo&rdquo; within the couple; for instance, a woman who fantasizes about another person to achieve orgasm is unlikely to admit this in the presence of her partner. How best to handle such private information should be agreed upon by all parties at the beginning of the assessment.",
"   </p>",
"   <p>",
"    Measures of genital sensory function, such as tactile, vibratory, and temperature perception thresholds, appear to show some correlation with orgasmic function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/40\">",
"     40",
"    </a>",
"    ]; however, they lack sufficient sensitivity and specificity for use in detecting problems with orgasm in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A medical work-up may be useful if the patient experiences a relatively sudden, generalized, and persistent loss of orgasmic response in the absence of other obvious causal factors. A physical exam can also rule out causes of genital discomfort or dyspareunia that contribute to sexual difficulties. The medical evaluation of women with sexual dysfunction is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25258?source=see_link&amp;anchor=H20#H20\">",
"     \"Sexual dysfunction in women: Epidemiology, risk factors, and evaluation\", section on 'Diagnostic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A detailed assessment of patients with sexual dysfunction is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/57/42904?source=see_link\">",
"     \"The sexual history and approach to the patient with sexual dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12710883\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The DSM-IV-TR criteria for female orgasmic disorder are as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Persistent or recurrent delay, or absence of orgasm following a normal sexual excitement phase. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25258?source=see_link&amp;anchor=H2#H2\">",
"       \"Sexual dysfunction in women: Epidemiology, risk factors, and evaluation\", section on 'Female sexual response cycle'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The disturbance causes marked distress or interpersonal difficulty.",
"     </li>",
"     <li>",
"      The orgasmic dysfunction is not better accounted for by another Axis I disorder (except another sexual dysfunction) and is not due exclusively to the direct physiological effects of a substance or a general medical condition.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One diagnostic question is whether the woman is anorgasmic despite the presence of a &ldquo;normal sexual excitement phase.&rdquo; This requires careful investigation of the woman&rsquo;s degree of sexual interest and arousal. The absence of an orgasm is an expected consequence of a sexual encounter that is not arousing. Despite this, sexual arousal is easy to overlook in the course of a clinical interview. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25258?source=see_link&amp;anchor=H2#H2\">",
"     \"Sexual dysfunction in women: Epidemiology, risk factors, and evaluation\", section on 'Female sexual response cycle'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Female orgasmic disorder may be diagnosed concurrently with one or more other sexual disorders. However, if problems with orgasm occur exclusively within the context of low sexual desire or arousal, then it is difficult to establish whether orgasm would occur following a &ldquo;normal sexual excitement phase&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Female orgasmic disorder should only be diagnosed in women who experience marked distress or interpersonal difficulty due to absent or delayed orgasm. Most women seeking treatment for a sexual problem are significantly distressed. It is nevertheless worthwhile to inquire about the impact of the problem on the woman&rsquo;s life and the nature of her concern. In some cases, the woman may not be distressed by the absence of orgasm itself, but by it causing her to worry about whether she is &ldquo;normal.&rdquo; Alternatively, the woman&rsquo;s partner may look upon her lack of orgasm as a reflection of his or her own desirability or competence as a lover. In these instances, a diagnosis is not necessarily appropriate, particularly if the woman does not otherwise perceive her response as problematic. In this case, the issues should be reframed as an opportunity to educate the woman and her partner about typical variations in sexual response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12710909\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of female orgasmic disorder includes medical and substance-induced conditions, iatrogenic causes, and other mental disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12711023\">",
"    <span class=\"h3\">",
"     Medical conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of medical conditions can cause sexual dysfunction in women; these are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25258?source=see_link&amp;anchor=H22#H22\">",
"     \"Sexual dysfunction in women: Epidemiology, risk factors, and evaluation\", section on 'Medical history'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12711277\">",
"    <span class=\"h3\">",
"     Substance-induced conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute intoxication with central nervous system depressants such as alcohol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/43\">",
"     43",
"    </a>",
"    ] may inhibit orgasmic response. &nbsp;Substance use that can cause sexual dysfunction in woman is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25258?source=see_link&amp;anchor=H18#H18\">",
"     \"Sexual dysfunction in women: Epidemiology, risk factors, and evaluation\", section on 'Substance use'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12711291\">",
"    <span class=\"h3\">",
"     Iatrogenic causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired orgasmic dysfunction is more commonly due to iatrogenic causes than caused by a medical condition. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), is commonly associated with delayed orgasm in both men and women. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2039?source=see_link\">",
"       \"Sexual dysfunction associated with selective serotonin reuptake inhibitor (SSRI) antidepressants\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antipsychotic drugs are associated with orgasmic dysfunction, particularly first-generation neuroleptics [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/44\">",
"       44",
"      </a>",
"      ]. These effects may be due to anti-dopaminergic properties and induced hyperprolactinemia. Second-generation antipsychotics appear less likely to cause these side effects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/45-47\">",
"       45-47",
"      </a>",
"      ]. A recent meta-analysis found orgasmic dysfunction to be reported in fewer than 10 percent of women taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"       aripiprazole",
"      </a>",
"      , compared to more than 20 percent of women receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A short-term decrement in orgasmic function may follow pelvic surgery or vaginal childbirth. Long-term orgasmic capacity is usually unaffected by routine pelvic surgeries, including simple hysterectomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/49,50\">",
"       49,50",
"      </a>",
"      ]. More radical pelvic surgeries and pelvic radiotherapy have greater potential to disrupt orgasmic functioning for a longer period of time compared to routine pelvic surgeries. As an example, long-term survivors of vaginal and cervical cancers report orgasmic problems at about twice the rate of women in the general population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/51\">",
"       51",
"      </a>",
"      ]. Women who have undergone cancer treatment are also more likely to have problems with sexual desire, arousal, and pain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12711302\">",
"    <span class=\"h3\">",
"     Other mental disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Problems with orgasm are not a typical symptom of other mental disorders but may accompany manifestations of mood disturbance or anxiety. As an example, a diagnosis of depression is associated with a loss of interest in sex, which may lead to secondary orgasmic dysfunction. Population-based studies have found that depression is a risk factor for orgasm problems in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36600/abstract/11\">",
"     11",
"    </a>",
"    ], although it is unclear whether this reflects the widespread use of antidepressant medication. Anxiety that distracts the woman from attending to sexual stimulation (eg, uncontrollable worry) or creates psychological discomfort with sexual stimulation (eg, contamination fears) may also contribute to problems with orgasm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7344456\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Female orgasmic disorder is characterized by a persistent or recurrent delay in or absence of orgasm following sexual arousal and adequate sexual stimulation, with the symptoms causing marked distress or interpersonal difficulty. Female orgasmic disorder may be lifelong or acquired, generalized or situational. (See",
"      <a class=\"local\" href=\"#H7344372\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/48/2824?source=see_link&amp;anchor=H578730518#H578730518\">",
"       \"Treatment of female orgasmic disorder\", section on 'Introduction'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H457298724\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Epidemiologic studies have found the estimated prevalence of orgasmic dysfunction to vary internationally from 20 to 40 percent; however, the prevalence of female orgasmic disorder is lower than these estimates, because diagnostic criteria for female orgasmic disorder require that the symptoms are distressing or bothersome to the respondent. (See",
"      <a class=\"local\" href=\"#H7344379\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although female orgasmic disorder may manifest as a complete absence of orgasm, some women with acquired female orgasmic disorder report delayed orgasm (ie, requiring longer",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      more intense stimulation to reach orgasm) or a less intense experience of orgasm. Women may also report a sense of impending orgasm that does not reach a peak or resolution despite continued stimulation. (See",
"      <a class=\"local\" href=\"#H7344407\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of female orgasmic disorder includes medical and substance-induced conditions (such as multiple sclerosis and alcohol intoxication), iatrogenic causes (including serotonergic antidepressants and pelvic surgery), and other mental disorders (such as major depression). (See",
"      <a class=\"local\" href=\"#H12710909\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2039?source=see_link\">",
"       \"Sexual dysfunction associated with selective serotonin reuptake inhibitor (SSRI) antidepressants\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25258?source=see_link&amp;anchor=H22#H22\">",
"       \"Sexual dysfunction in women: Epidemiology, risk factors, and evaluation\", section on 'Medical history'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), Fourth edition, Text revision, American Psychiatric Association, Washington, DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/2\">",
"      Bancroft J, Loftus J, Long JS. Distress about sex: a national survey of women in heterosexual relationships. Arch Sex Behav 2003; 32:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/3\">",
"      Hayes RD, Bennett CM, Fairley CK, Dennerstein L. What can prevalence studies tell us about female sexual difficulty and dysfunction? J Sex Med 2006; 3:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/4\">",
"      Laumann EO, Glasser DB, Neves RC, et al. A population-based survey of sexual activity, sexual problems and associated help-seeking behavior patterns in mature adults in the United States of America. Int J Impot Res 2009; 21:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/5\">",
"      Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999; 281:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/6\">",
"      Read S, King M, Watson J. Sexual dysfunction in primary medical care: prevalence, characteristics and detection by the general practitioner. J Public Health Med 1997; 19:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/7\">",
"      Rosen RC, Taylor JF, Leiblum SR, Bachmann GA. Prevalence of sexual dysfunction in women: results of a survey study of 329 women in an outpatient gynecological clinic. J Sex Marital Ther 1993; 19:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/8\">",
"      Richters J, Grulich AE, de Visser RO, et al. Sex in Australia: sexual difficulties in a representative sample of adults. Aust N Z J Public Health 2003; 27:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/9\">",
"      Shifren JL, Monz BU, Russo PA, et al. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol 2008; 112:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/10\">",
"      Keller A, McGarvey EL, Clayton AH. Reliability and construct validity of the Changes in Sexual Functioning Questionnaire short-form (CSFQ-14). J Sex Marital Ther 2006; 32:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/11\">",
"      Laumann EO, Nicolosi A, Glasser DB, et al. Sexual problems among women and men aged 40-80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. Int J Impot Res 2005; 17:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/12\">",
"      Derogatis LR, Rosen R, Leiblum S, et al. The Female Sexual Distress Scale (FSDS): initial validation of a standardized scale for assessment of sexually related personal distress in women. J Sex Marital Ther 2002; 28:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/13\">",
"      Hayes RD, Dennerstein L, Bennett CM, Fairley CK. What is the \"true\" prevalence of female sexual dysfunctions and does the way we assess these conditions have an impact? J Sex Med 2008; 5:777.",
"     </a>",
"    </li>",
"    <li>",
"     Nichols M. Sexual function in women with women: Lesbians and lesbian relationships. In: Women's Sexual Function and Dysfunction: Study, Diagnosis and Treatment, Goldstein I, Meston CM, Davis SR, Traish AM.  (Eds), Taylor &amp; Francis, London 2006. p.307.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/15\">",
"      Hayes R, Dennerstein L. The impact of aging on sexual function and sexual dysfunction in women: a review of population-based studies. J Sex Med 2005; 2:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/16\">",
"      Fugl-Meyer KS, Oberg K, Lundberg PO, et al. On orgasm, sexual techniques, and erotic perceptions in 18- to 74-year-old Swedish women. J Sex Med 2006; 3:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/17\">",
"      Harris JM, Cherkas LF, Kato BS, et al. Normal variations in personality are associated with coital orgasmic infrequency in heterosexual women: a population-based study. J Sex Med 2008; 5:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/18\">",
"      Dunn KM, Croft PR, Hackett GI. Association of sexual problems with social, psychological, and physical problems in men and women: a cross sectional population survey. J Epidemiol Community Health 1999; 53:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/19\">",
"      Aksaray G, Yelken B, Kaptanolu C, et al. Sexuality in women with obsessive compulsive disorder. J Sex Marital Ther 2001; 27:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/20\">",
"      Komisaruk BR, Whipple B, Crawford A, et al. Brain activation during vaginocervical self-stimulation and orgasm in women with complete spinal cord injury: fMRI evidence of mediation by the vagus nerves. Brain Res 2004; 1024:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/21\">",
"      Whipple B, Komisaruk BR. Brain (PET) responses to vaginal-cervical self-stimulation in women with complete spinal cord injury: preliminary findings. J Sex Marital Ther 2002; 28:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/22\">",
"      Henton CL. Nocturnal orgasm in college women: its relation to dreams and anxiety associated with sexual factors. J Genet Psychol 1976; 129:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/23\">",
"      Wells BL. Predictors of female nocturnal orgasms: A multivariate analysis. J Sex Res 1986; 22:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/24\">",
"      Whipple B, Ogden G, Komisaruk BR. Physiological correlates of imagery-induced orgasm in women. Arch Sex Behav 1992; 21:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/25\">",
"      Clifford R. Development of masturbation in college women. Arch Sex Behav 1978; 7:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/26\">",
"      Gravina GL, Brandetti F, Martini P, et al. Measurement of the thickness of the urethrovaginal space in women with or without vaginal orgasm. J Sex Med 2008; 5:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/27\">",
"      Wallen K, Lloyd EA. Female sexual arousal: genital anatomy and orgasm in intercourse. Horm Behav 2011; 59:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/28\">",
"      Dawood K, Kirk KM, Bailey JM, et al. Genetic and environmental influences on the frequency of orgasm in women. Twin Res Hum Genet 2005; 8:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/29\">",
"      Dunn KM, Cherkas LF, Spector TD. Genetic influences on variation in female orgasmic function: a twin study. Biol Lett 2005; 1:260.",
"     </a>",
"    </li>",
"    <li>",
"     Masters WH, Johnson VE. Human Sexual Inadequacy, Little, Brown and Company, Boston, MA 1970.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/31\">",
"      McCarthy BW. Strategies and techniques for the reduction of sexual anxiety. J Sex Marital Ther 1977; 3:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/32\">",
"      Bancroft J, Graham CA, Janssen E, Sanders SA. The dual control model: current status and future directions. J Sex Res 2009; 46:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/33\">",
"      Sanders SA, Graham CA, Milhausen RR. Predicting sexual problems in women: the relevance of sexual excitation and sexual inhibition. Arch Sex Behav 2008; 37:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/34\">",
"      Kelly MP, Strassberg DS, Kircher JR. Attitudinal and experiential correlates of anorgasmia. Arch Sex Behav 1990; 19:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/35\">",
"      Kelly MP, Strassberg DS, Turner CM. Communication and associated relationship issues in female anorgasmia. J Sex Marital Ther 2004; 30:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/36\">",
"      Kelly MP, Strassberg DS, Turner CM. Behavioral assessment of couples' communication in female orgasmic disorder. J Sex Marital Ther 2006; 32:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/37\">",
"      Meston CM, Levin RJ, Sipski ML, et al. Women's orgasm. Annu Rev Sex Res 2004; 15:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/38\">",
"      Ahrold TK, Farmer M, Trapnell PD, Meston CM. The relationship among sexual attitudes, sexual fantasy, and religiosity. Arch Sex Behav 2011; 40:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/39\">",
"      Mercer CH, Fenton KA, Johnson AM, et al. Sexual function problems and help seeking behaviour in Britain: national probability sample survey. BMJ 2003; 327:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/40\">",
"      Helpman L, Greenstein A, Hartoov J, Abramov L. Genito-sensory analysis in women with arousal and orgasmic dysfunction. J Sex Med 2009; 6:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/41\">",
"      Esposito K, Ciotola M, Giugliano F, et al. Quantitative sensory and autonomic testing in nondiabetic women with sexual dysfunction. J Sex Med 2007; 4:1367.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), Fourth edition, Text revision, American Psychiatric Association, Washington, DC 2000. p.549.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/43\">",
"      Malatesta VJ, Pollack RH, Crotty TD, Peacock LJ. Acute alcohol intoxication and female orgasmic response. J Sex Res 1982; 18:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/44\">",
"      Smith SM, O'Keane V, Murray R. Sexual dysfunction in patients taking conventional antipsychotic medication. Br J Psychiatry 2002; 181:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/45\">",
"      Byerly MJ, Lescouflair E, Weber MT, et al. An open-label trial of quetiapine for antipsychotic-induced sexual dysfunction. J Sex Marital Ther 2004; 30:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/46\">",
"      Bobes J, Garc A-Portilla MP, Rejas J, et al. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J Sex Marital Ther 2003; 29:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/47\">",
"      Baggaley M. Sexual dysfunction in schizophrenia: focus on recent evidence. Hum Psychopharmacol 2008; 23:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/48\">",
"      Serretti A, Chiesa A. A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. Int Clin Psychopharmacol 2011; 26:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/49\">",
"      Pauls RN. Impact of gynecological surgery on female sexual function. Int J Impot Res 2010; 22:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/50\">",
"      Farquhar CM, Sadler L, Stewart AW. A prospective study of outcomes five years after hysterectomy in premenopausal women. Aust N Z J Obstet Gynaecol 2008; 48:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/51\">",
"      Lindau ST, Gavrilova N, Anderson D. Sexual morbidity in very long term survivors of vaginal and cervical cancer: a comparison to national norms. Gynecol Oncol 2007; 106:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36600/abstract/52\">",
"      Sadovsky R, Basson R, Krychman M, et al. Cancer and sexual problems. J Sex Med 2010; 7:349.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14810 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-C070ECA3F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_47_36600=[""].join("\n");
var outline_f35_47_36600=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7344456\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7344372\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H457298724\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H457298731\">",
"      Primary female orgasmic disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H457298738\">",
"      Secondary female orgasmic disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7344379\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4531689\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4531773\">",
"      Comorbid disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7344480\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7344386\">",
"      Normal functioning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7344393\">",
"      Psychological and cultural factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12710668\">",
"      - Intrapsychic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12710675\">",
"      - Relationship factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12710687\">",
"      - Sociocultural factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7344407\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7344414\">",
"      COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7344421\">",
"      ASSESSMENT AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12710883\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12710909\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12711023\">",
"      - Medical conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12711277\">",
"      - Substance-induced conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12711291\">",
"      - Iatrogenic causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12711302\">",
"      - Other mental disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7344456\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2039?source=related_link\">",
"      Sexual dysfunction associated with selective serotonin reuptake inhibitor (SSRI) antidepressants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25258?source=related_link\">",
"      Sexual dysfunction in women: Epidemiology, risk factors, and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/10/34985?source=related_link\">",
"      Sexual dysfunction in women: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/57/42904?source=related_link\">",
"      The sexual history and approach to the patient with sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/48/2824?source=related_link\">",
"      Treatment of female orgasmic disorder",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_47_36601="Medical management of the dialysis patient undergoing surgery";
var content_f35_47_36601=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Medical management of the dialysis patient undergoing surgery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/47/36601/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/47/36601/contributors\">",
"     Ramesh Soundararajan, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/47/36601/contributors\">",
"     Thomas A Golper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/47/36601/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/47/36601/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/47/36601/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/47/36601/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/47/36601/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A paucity of information exists concerning the optimum medical management of the dialysis patient undergoing surgery. General issues include the preoperative evaluation, the delivery of dialysis in the period surrounding or during the surgery, intraoperative concerns (including anesthesia), and postoperative management (such as pain control).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SURGICAL MORBIDITY AND MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based in part upon the type of surgery, dialysis patients experience a varying degree of morbidity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among those who undergo general surgery, the combined mortality reported in eight published studies was approximately 4 percent, ranging between a low of 0 percent to a high of 47 percent in emergency cases. The morbidity rate was 54 percent (range 12 to 64 percent).",
"     </li>",
"     <li>",
"      Among 13 separate studies, cardiac surgery resulted in mortality and morbidity rates of 10 and 46 percent, respectively. The mortality associated with valvular repair was twice that of coronary artery bypass grafting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The cause of the increased morbidity and mortality with dialysis may be attributed to a number of factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A high incidence of coronary artery disease and myocardial dysfunction.",
"     </li>",
"     <li>",
"      Difficulty adjusting fluid and electrolytes in the perioperative period in patients who are anephric. Hyperkalemia is the most common complication [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/2\">",
"       2",
"      </a>",
"      ], possibly requiring immediate postoperative dialysis.",
"     </li>",
"     <li>",
"      Failure to normally excrete",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      metabolize anesthetics and analgesics, leading to toxic levels of these agents.",
"     </li>",
"     <li>",
"      Increased bleeding complications.",
"     </li>",
"     <li>",
"      Poor blood pressure control, including hypertension and hypotension.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dialysis patients also appear to require significantly increased medical support. This includes an increased need for vasopressors and antihypertensive agents, an enhanced time on mechanical ventilators, and an increased number of days in intensive care and the hospital [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MEDICAL MANAGEMENT OF THE DIALYSIS PATIENT UNDERGOING SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal pre-, peri,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    postoperative issues of concern relating to the medical management of the dialysis patients include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      General laboratory evaluation",
"     </li>",
"     <li>",
"      Anemia status",
"     </li>",
"     <li>",
"      Nutritional status",
"     </li>",
"     <li>",
"      Dialysis dose",
"     </li>",
"     <li>",
"      Fluid and electrolyte management",
"     </li>",
"     <li>",
"      Blood pressure control",
"     </li>",
"     <li>",
"      Evaluation for cardiovascular disease and the use of beta blocker medication",
"     </li>",
"     <li>",
"      Correction of a bleeding diathesis",
"     </li>",
"     <li>",
"      Antibiotic administration",
"     </li>",
"     <li>",
"      Glucose metabolism",
"     </li>",
"     <li>",
"      Intravenous access",
"     </li>",
"     <li>",
"      Anesthetic considerations",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A baseline set of electrolyte values, serum concentrations of glucose, blood urea nitrogen, creatinine, calcium, phosphorus, magnesium, and albumin, as well as a complete blood count and coagulation profile should be performed in all patients. We only perform bleeding times prior to a renal biopsy.",
"   </p>",
"   <p>",
"    The frequency and type of additional laboratory testing should be tailored to the requirements of the individual patient:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the patient is anemic, iron studies should be performed (if not recently done).",
"     </li>",
"     <li>",
"      If appropriate, the serum concentration of certain drugs, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      , should be measured.",
"     </li>",
"     <li>",
"      Blood glucose levels should be monitored closely in diabetic patients, both prior to and after surgery, particularly when the patient cannot ingest food (see below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Anemia status",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the surgery is elective and can be planned for several weeks to months in the future, it is possible to boost the hemoglobin concentration to optimum levels by the judicious use of additional erythropoiesis-stimulating agents (ESAs). This is important because transfusions are frequently necessary postoperatively due to substantial intra- or postoperative blood loss and the postoperative state is characterized by ESA resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability to heal after surgery may be maximized by ensuring that the dialysis patient is well-nourished. In turn, the nutritional status appears to be related to the delivery of appropriate amounts of dialysis.",
"   </p>",
"   <p>",
"    Although the optimal dose of dialysis is unknown, the delivery of adequate amounts promotes a healthy appetite and enhances overall nutrition. Parameters utilized to assess nutritional status and therefore dialysis adequacy, such as the protein catabolic rate and serum concentration of albumin, should be optimized prior to the operation, if possible. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/17/277?source=see_link\">",
"     \"Protein catabolic rate in maintenance dialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/2/15399?source=see_link\">",
"     \"Assessment of nutritional status in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Current minimum recommendations for dialysis dose and nutritional parameters include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      1.3 to 1.4 for the",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      in hemodialysis",
"     </li>",
"     <li>",
"      1.7 for the weekly",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      in continuous peritoneal dialysis",
"     </li>",
"     <li>",
"      1.0 to 1.2",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per day for the protein catabolic rate",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/14/6378?source=see_link\">",
"     \"Kt/V and the adequacy of hemodialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/58/1962?source=see_link\">",
"     \"Adequacy of peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other measures that can be used to improve the nutritional status of patients include the elimination of drugs which impair appetite, the institution of therapies to ameliorate gastroparesis, and the use of nutritional supplements. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/3/9274?source=see_link\">",
"     \"Pathogenesis and treatment of malnutrition in maintenance dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Intensive dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether the delivery of intensive doses of dialysis prior to or during surgery improves outcomes is unknown. Among the recommendations that have been made are daily dialysis for a few days prior to cardiac surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/4\">",
"     4",
"    </a>",
"    ] and intraoperative hemodialysis during cardiac surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. In one study of 13 hemodialysis patients, six received routine dialysis and seven underwent intraoperative hemodialysis during open-heart surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/6\">",
"     6",
"    </a>",
"    ]. Compared to those undergoing routine dialysis, fewer patients receiving intraoperative dialysis required bicarbonate therapy postsurgery and postoperative dialysis could be delayed for one day (two versus one day).",
"   </p>",
"   <p>",
"    With peritoneal dialysis, about a week before surgery:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An additional exchange each day for continuous ambulatory peritoneal dialysis patients seems a reasonable approach",
"     </li>",
"     <li>",
"      An extra hour or two on the cycler each day for automated peritoneal dialysis patients may also be helpful",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another goal of additional dialysis preoperatively is to reassess and achieve the dry weight, which is often changing. Untoward responses to anesthesia frequently require fluid challenges so entering surgery at an appropriate (and correct) dry weight is suggested (see next section).",
"   </p>",
"   <p>",
"    Despite these benefits, an improvement in mortality has not been observed with the institution of intensive dialysis. In general, dialysis should at least be provided the day before surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Fluid and electrolyte issues prior to surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dialysis is occasionally provided immediately prior to surgery. In this setting, it is important to institute measures which avoid prolonged anticoagulation (by providing dialysis without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    ), which ensure that hypercalcemia and hypokalemia are not induced during the postdialysis period (by adjusting dialysate concentrations), and which remove an adequate amount of total body fluid. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/14/38120?source=see_link\">",
"     \"Hemodialysis anticoagulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Achieving optimal volume status prior to surgery is based in part upon correctly estimating the amount of fluid to be administered",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lost during surgery:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If euvolemia or \"dry weight\" (which is an estimated guess) is achieved and the patient receives a large volume of fluid during surgery, hypervolemia and possibly pulmonary edema can occur in the immediate postoperative period, thereby necessitating dialysis.",
"     </li>",
"     <li>",
"      If too much fluid is removed, there is the risk of hypotension during anesthesia-induced systemic vasodilatation; this can cause many significant complications, including, but not limited to, thrombosis of the arteriovenous access.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a result, a discussion with the surgeon and anesthesiologist regarding perioperative volume status goals is desirable. The type of intraoperative fluid administered should also be reviewed. In patients without renal failure, the most common intraoperative fluid given is \"lactated Ringers,\" a solution that contains potassium. Thus, the preferred solution in dialysis patients is isotonic saline. However, based upon the specific acid-base and electrolyte abnormalities, different fluids may be required, including specially tailored solutions.",
"   </p>",
"   <p>",
"    With elective surgery, fluid and electrolyte levels should be optimized with preoperative dialysis. With respect to potassium, hemodialysis can remove 25 to 50 meq of potassium per hour, with variability based upon the initial serum potassium concentration, the dialyzer, the blood flood rate, and the potassium concentration of the bath [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/7\">",
"     7",
"    </a>",
"    ]. In general, two hours of hemodialysis will suffice to prepare a patient for emergency surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Hyperkalemia and emergency surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the surgery is emergent or access-related, it may not be possible to undergo dialysis in the immediate preoperative period. In this setting, hyperkalemia is the most common and important electrolyte abnormality that has to be addressed.",
"   </p>",
"   <p>",
"    The preoperative evaluation in patients with an elevated serum potassium concentration includes a twelve lead electrocardiogram, which assesses the physiologic effect of hyperkalemia. Chronic dialysis patients often have an increased tolerance for hyperkalemia as electrocardiographic changes are frequently not seen until the serum potassium concentration exceeds 6.0 to 6.5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/7\">",
"     7",
"    </a>",
"    ]. Changes in the electrocardiogram with hyperkalemia are thought to result from alterations in the transcellular potassium gradient, rather than the absolute value of the serum potassium. Dialysis patients often have elevations in total body and intracellular potassium; as a result, the transcellular gradient may not be altered with moderate hyperkalemia, resulting in the absence of hyperkalemic changes on the electrocardiogram.",
"   </p>",
"   <p>",
"    In general, judgment as to the best course of action is based upon the clinical setting (eg, tissue damage and release of potassium during the operation), the urgency for surgery, and whether it is safe to delay surgery for three to four hours while the patient is dialyzed.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If there are no electrocardiographic changes and the patient is otherwise stable, an individual with a serum potassium of 6.0 to 6.2",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      should be able to safely undergo emergency surgery with close intraoperative monitoring by anesthesiologists [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If electrocardiographic features of hyperkalemia are present and dialysis",
"      <strong>",
"       cannot",
"      </strong>",
"      be performed prior to surgery, medical management should be initiated. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/54/17258?source=see_link\">",
"       \"Treatment and prevention of hyperkalemia in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since hypertension is common in the dialysis population, significantly elevated blood pressure levels measured prior to surgery may require immediate therapy. With dialysis patients, initial therapy of hypertension should aim to optimize volume status via the fluid removal with dialysis, since volume overload is likely to be causative. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/46/20202?source=see_link\">",
"     \"Hypertension in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antihypertensive therapy may be necessary if the blood pressure remains high despite the attainment of optimal dry weight, or if dialysis cannot be performed in the immediate-preoperative period because the surgery is emergent or access-related. In this setting, parenteral antihypertensive therapy is frequently. Agents most commonly used include intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/22/20839?source=see_link\">",
"     enalaprilat",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35544?source=see_link\">",
"     labetalol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    (which should be given with beta blockers to minimize the effect of reflex sympathetic activation),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nitroglycerine. If the patient is monitored in the intensive care unit, intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    may also be utilized. The use of parenteral medications in dialysis patients is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/58/22440?source=see_link&amp;anchor=H9#H9\">",
"     \"Seizures in patients undergoing hemodialysis\", section on 'Hypertensive encephalopathy'",
"    </a>",
"    .)The benefits of using beta blockers in this setting are discussed below. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Cardiovascular evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Transdermal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    requires a longer time to achieve adequate blood levels and may not immediately control blood pressure. It may be more useful postoperatively or when blood pressure control is less urgent.",
"   </p>",
"   <p>",
"    Once oral intake is tolerated, the normal antihypertensive regimen may be reinstituted. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/46/20202?source=see_link\">",
"     \"Hypertension in dialysis patients\"",
"    </a>",
"    .) In some settings, these medications may have to be gradually introduced",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    staggered; precise blood pressure limits for withholding",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    giving medications or doses may be needed as the patient's requirements for antihypertensive therapy may differ in the acute postoperative setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hypotension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypotension in dialysis patients may result from a number of factors. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Excessive fluid removal in dialysis, which is most common",
"     </li>",
"     <li>",
"      Left ventricular dysfunction",
"     </li>",
"     <li>",
"      Interference with sympathetic function due to diabetic autonomic neuropathy, acquired dysautonomia of recumbency, or the administration of sympatholytic medications",
"     </li>",
"     <li>",
"      Pericardial tamponade",
"     </li>",
"     <li>",
"      Vasodilation from opioid analgesics or other medications administered to alleviate pain or anxiety",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/32/31240?source=see_link\">",
"     \"Hemodynamic instability during hemodialysis: Overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional factors may underlie relative hypotension in dialysis patients who are hospitalized. Such patients usually require fewer",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lower doses of antihypertensive medications since they are generally more compliant with salt and fluid restriction and are dialyzed more frequently. As a result, antihypertensive drugs may need to be titrated or actually held prior to dialysis, particularly when aggressive fluid removal is planned.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cardiovascular evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary artery disease and myocardial dysfunction are the most common comorbidities in patients with renal failure. In some series, approximately 50 percent of dialysis patients undergoing surgery are thought to have cardiovascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/2,9\">",
"     2,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Heart disease results in significant morbidity and mortality in patients with end-stage renal disease, even among those not undergoing surgery. As an example, in one prospective study of 305 dialysis patients followed for a four-year period, 114 cardiovascular events and 89 deaths were reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/10\">",
"     10",
"    </a>",
"    ]. The mortality was 10 times that of the general population, including 44 times higher in diabetic patients with renal disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/49/33559?source=see_link\">",
"     \"Clinical manifestations and diagnosis of coronary heart disease in end-stage renal disease (dialysis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Clinical evaluation of cardiac risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of patients with known or suspected cardiac disease prior to noncardiac surgery requires an appraisal of the patient's clinical risk profile in the context of the surgery to be performed and the attendant risks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/11\">",
"     11",
"    </a>",
"    ]. An American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association Task Force has published practice guidelines on perioperative cardiovascular evaluation for noncardiac surgery; they stress that the estimation of perioperative risk should integrate clinical determinants of risk including functional capacity, the surgery-specific risk, and the results of stress testing when it is performed (",
"    <a class=\"graphic graphic_table graphicRef69468 \" href=\"mobipreview.htm?34/22/35179\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36810?source=see_link\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One study utilized such a clinical risk stratification for patients with end-stage renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/13\">",
"     13",
"    </a>",
"    ]. Patients were first stratified on the basis of age (less than or greater than 50 years old), a history of angina, type 1 diabetes, or congestive heart failure, or the presence of an abnormal electrocardiogram (excluding left ventricular hypertrophy). Among the approximately 50 percent of patients who had none of these characteristics, no further cardiac testing was undertaken (low-risk group). Patients had one or more risk factor underwent thallium myocardial scintigraphy (high-risk group). Overall cardiac mortality was 17 and 1 percent in the high-risk and low-risk groups, respectively. In the high-risk group, patients with reversible thallium defects had significantly higher cardiac mortality rates than those without such defects (23 versus 5 percent).",
"   </p>",
"   <p>",
"    Thus, clinical criteria can stratify patients according to risk:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients at low risk generally require no further evaluation before surgery.",
"     </li>",
"     <li>",
"      Patients at high risk usually undergo coronary arteriography to see if any correctable lesions are present. The",
"      <span class=\"nowrap\">",
"       ACC/AHA",
"      </span>",
"      Committee on Coronary Angiography has published recommendations for the use of coronary angiography in these patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients at intermediate risk represent a heterogeneous group that includes those at low and high risk. The use of noninvasive testing in this group can identify the risk category of an individual patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further risk stratification in appropriate patients includes noninvasive evaluation for coronary disease and myocardial dysfunction. Most of the studies that have assessed these tests in patients with end-stage renal disease utilized patients who were candidates for renal transplantation. As a result, there was a selection bias toward a relatively healthier dialysis population. A paucity of studies exists concerning the perioperative cardiac risk assessment for the general dialysis population.",
"   </p>",
"   <p>",
"    While not necessarily a study of dialysis patients, it has been shown in a well designed observational study that late stage CKD patients undergoing surgery and receiving concomitant beta blocker therapy had less post operative mortality than similar patients not on beta blockers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Noninvasive evaluation for coronary artery disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of noninvasive methods are available to screen for the presence of coronary artery disease when indicated. The accuracy of the different tests may be center-specific and is dependent upon the expertise of the examiner. There are also problems associated with renal failure. These include baseline abnormalities on the electrocardiogram and thallium scintigraphy induced by the abnormal metabolic milieu and a frequent inability to perform adequately during an exercise test.",
"   </p>",
"   <p>",
"    Many noninvasive techniques utilized to detect coronary artery disease, such as exercise testing using electrocardiography alone and exercise testing with thallium imaging, are not sufficiently accurate in dialysis patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/30/44520?source=see_link\">",
"     \"Selecting the optimal cardiac stress test\"",
"    </a>",
"    .) In one study, for example, exercise testing using the results of electrocardiography alone had a sensitivity of only 68 percent, even in those who reached 85 percent of the maximum heart rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/16\">",
"     16",
"    </a>",
"    ]. In another report, thallium-201 myocardial imaging with exercise failed to accurately predict cardiovascular risk in 189 dialysis patients with diabetic nephropathy who were being evaluated for a cadaveric renal transplant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By comparison,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    thallium-201 imaging may be more accurate in this patient population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. The range of findings can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One prospective study evaluated the predictive accuracy of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      -thallium-201 imaging among 36 diabetic and 29 nondiabetic patients undergoing evaluation for possible renal transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/17\">",
"       17",
"      </a>",
"      ]. Among the 35 without reversible defects who underwent transplant surgery, none had a perioperative cardiac event, and, at follow up of almost two years, only 9 percent had experienced a cardiac problem. All three patients with transient defects experienced a cardiac event, compared to 3 of 62 without a reversible lesion.",
"     </li>",
"     <li>",
"      Similar findings were noted in a series 40 patients who were being considered for renal transplantation; 9, 8, and 23 patients had reversible, fixed, and normal scans, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/18\">",
"       18",
"      </a>",
"      ]. The six patients who had cardiac events, three before surgery and three in the early postoperative period, all had reversible thallium defects.",
"     </li>",
"     <li>",
"      In a study of 60 asymptomatic hemodialysis patients who underwent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      -exercise thallium imaging and coronary angiography, the sensitivity, specificity, positive and negative predictive values, and overall accuracy of thallium imaging were 92, 89, 71, 98, and 90 percent, respectively. At follow-up of nearly three years, patients with an abnormal thallium image were significantly more likely to have had a significant coronary event (cardiac death, myocardial infarction, or need for revascularization) than those with a normal test (47 versus 9 percent, adjusted risk ratio 9.2, p&lt;0.005).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     Dobutamine",
"    </a>",
"    stress echocardiography (DSE) is another noninvasive test that may be highly accurate in patients with end-stage renal disease. In one report, 97 patients underwent DSE as part of a preoperative evaluation prior to possible transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/20\">",
"     20",
"    </a>",
"    ]. Thirty and 25 patients also underwent coronary angiography and renal transplantation, respectively. Dobutamine stress echocardiography had a sensitivity of 95 percent, a specificity of 86 percent, and an accuracy of 90 percent for the detection of coronary artery disease. A normal stress examination also identified those who were at very low risk (3 percent) for a coronary event in the ensuing year.",
"   </p>",
"   <p>",
"    A preliminary study compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography with coronary angiography in renal transplant candidates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/21\">",
"     21",
"    </a>",
"    ]. Compared with coronary angiography (the gold standard), DSE had a specificity, sensitivity, positive predictive value, and negative predictive value of 86, 91, 84, and 92 percent, respectively.",
"   </p>",
"   <p>",
"    Discussion with the cardiologist regarding the optimal imaging techniques for risk stratification in individual patients as well as institutional preferences is important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Noninvasive evaluation for myocardial dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to coronary artery disease, left ventricular dysfunction is associated with significantly increased risk in patients undergoing surgery. Preoperatively, its presence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severity can be evaluated noninvasively with either an echocardiogram or radionuclide scan. Such an evaluation is most useful to evaluate ventricular dysfunction in poorly controlled heart failure or heart failure of uncertain cause. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/21/11610?source=see_link\">",
"     \"Noninvasive methods for measurement of left ventricular systolic function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although it is operator dependent, two-dimensional echocardiography is preferred since it provides details about valvular anomalies and approximate pressures in the ventricular chambers. If the study is suboptimal, a transesophageal echocardiogram or radionuclide ventriculography can be obtained.",
"   </p>",
"   <p>",
"    In addition to identifying patients who may require coronary angiography",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    who are at high-risk with surgery, the results of these noninvasive studies may suggest preoperative procedures that may reduce perioperative cardiac morbidity (particularly in patients with known or suspected coronary disease). These measures include maximizing drug therapy preoperatively (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/45/40666?source=see_link\">",
"     \"Perioperative medication management\"",
"    </a>",
"    ), prophylactic revascularization, and intraoperative monitoring. The data derived could also help determine the requirement for intensive preoperative and postoperative dialysis to maintain euvolemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Emergency surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need to perform immediate surgery may preclude the ability to adequately assess the cardiac risk of surgery. In this setting, the risk",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    benefits of immediate surgery must be weighed against the possibility of inducing a cardiovascular event in those at risk of having significant cardiovascular disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Bleeding diathesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased tendency to bleeding may be present in both acute and chronic renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/22\">",
"     22",
"    </a>",
"    ]. This is frequently manifested by bleeding at sites of surgery or trauma. However, not all uremic patients have a bleeding diathesis and some are actually hypercoagulable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Uremic bleeding appears to correlate most closely with prolongation of the bleeding time, due primarily to impaired platelet function. Some studies have found a good correlation between clinical bleeding and the bleeding time measured either on the arm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/24\">",
"     24",
"    </a>",
"    ] or thigh [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/25\">",
"     25",
"    </a>",
"    ]. However, some clinicians question the value of a bleeding time in this situation, since a normal bleeding time does not predict the safety of surgical procedures, nor does a prolonged bleeding time predict excessive bleeding. In addition, since assessment of the bleeding time may be subject to considerable variation due to technical factors in executing the test, it is not recommended as a preoperative screening test. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/3/5178?source=see_link&amp;anchor=H13#H13\">",
"     \"Approach to the adult patient with a bleeding diathesis\", section on 'Bleeding time'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is likely that multiple factors are responsible for the platelet dysfunction in uremia. These include retention of uremic toxins due in part to inadequate dialysis, anemia, excess parathyroid hormone, and the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/30/10727?source=see_link\">",
"     \"Platelet dysfunction in uremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other than before a renal biopsy, we do not routinely obtain a bleeding time prior to surgery. However, we measure the bleeding time in patients with bleeding complications after surgery who do not have an obvious cause for a bleeding diathesis, such as those with normal prothrombin and partial thromboplastin times, and normal platelet counts.",
"   </p>",
"   <p>",
"    Correction of the platelet dysfunction is recommended in patients with an elevated bleeding time who are actively bleeding. A number of different modalities can be used in this setting, which varies in their onset and duration of action.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Raising the hematocrit to 25 to 30 percent by blood transfusions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/26\">",
"       26",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"       Desmopressin",
"      </a>",
"      (dDAVP) at a dose of 0.30",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      either intravenously or intranasally has an effect that begins within one hour and lasts 4 to 24 hours [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/22\">",
"       22",
"      </a>",
"      ]; the combination of dDAVP and correction of anemia may have an additive effect on lowering the bleeding time",
"     </li>",
"     <li>",
"      Cryoprecipitate (10 units intravenously every 12 to 24 hours) has an effect that lasts 8 to 24 hours [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/27\">",
"       27",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Dialysis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The efficacy and use of these modalities is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/30/10727?source=see_link\">",
"     \"Platelet dysfunction in uremia\"",
"    </a>",
"    .) We initiate therapy by increasing the hematocrit (if low) and administering dDAVP. If there is no response, we next give cryoprecipitate. Estrogen, which has a more prolonged effect, is given to patients who require chronic control of the bleeding time, such as those with angiodysplasia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is preferable not to use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    during dialysis on the day of surgery. If heparin was administered, the coagulation profile should return to normal within",
"    <strong>",
"     four hours",
"    </strong>",
"    of heparin termination. Thus, if time permits, we wait for the coagulation parameters to normalize prior to beginning surgery. If more emergent surgery is required, the effect of heparin can be reversed by administering protamine. Heparin doses can be reduced and perhaps eliminated with the concomitant use of citrate containing dialysate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    saline flushes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=see_link\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After major surgery,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    with dialysis should be avoided for 24 to 48 hours, particularly if the site of surgery is not easy to assess for evidence of postoperative bleeding or if bleeding would result in catastrophic consequences. Discussion with the surgeon concerning these issues is vital. Alternatives to the administration of heparin are readily available, including no heparin hemodialysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/14/38120?source=see_link\">",
"     \"Hemodialysis anticoagulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Perioperative antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, perioperative antibiotics should be administered in accordance with general surgical principles, including appropriate dosing adjustments for patients with renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link\">",
"     \"Overview of control measures to prevent surgical site infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of control measures to prevent surgical site infection\", section on 'Antimicrobial prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients undergoing access procedures who receive antibiotics appear to have fewer access infections than those who do not receive such agents. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 408 vascular access procedures, only 1 percent of patients who received preoperative",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      developed graft infection as compared to 6 percent of those not administered any antibiotics [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 67 children, peritonitis occurring within 14 days of peritoneal dialysis catheter placement was significantly more common in patients who did not receive prophylaxis antibiotics (7 of 16 patients) compared to those who did (5 of 61 patients) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/30\">",
"       30",
"      </a>",
"      ]. The Network 9 study also showed a clear benefit from prophylactic antibiotics administered prior to peritoneal catheter placement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/31\">",
"       31",
"      </a>",
"      ]. By comparison, another report failed to show any benefit with prophylactic antibiotics [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/32\">",
"       32",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"       Cefazolin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      were the antibiotics used in this study.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, preoperative antibiotics are recommended for the placement of peritoneal dialysis catheters. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/63/6136?source=see_link\">",
"     \"Placement and maintenance of the peritoneal dialysis catheter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The loading dose of antibiotics is usually the same in dialysis patients as in normal individuals. Since the peak tissue level of antibiotics is commonly achieved one hour after infusion, the antibiotic infusion should be completed at least one hour prior to start of surgery to minimize the risk of surgical site infection in these high-risk patients.",
"   </p>",
"   <p>",
"    In general, the issues concerning the administration of preoperative antibiotics are the same in dialysis and nondialysis patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Glucose metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, approximately 44 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/33\">",
"     33",
"    </a>",
"    ] of dialysis patients have diabetes, of whom 10 percent have type I disease. Patients usually have better control of blood glucose levels at home than in the hospital because of multiple factors. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Change in physical activity",
"     </li>",
"     <li>",
"      Acute co-morbid conditions for which they have been hospitalized, such as infections, vomiting, and diarrhea",
"     </li>",
"     <li>",
"      Inability to ingest food",
"     </li>",
"     <li>",
"      The reality of hospital surgery schedules, such as the surgery scheduled at 8 AM that finally takes place at 4 PM",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific factors unique to type II diabetics may also contribute to difficult glucose control. The induction of hyperglycemia with surgery may be unappreciated and unrecognized in type II diabetics in whom all glycemic-control medications have been discontinued because of the decreased insulin requirements associated with end-stage renal disease. Conversely, because of the increased half-life of some oral hypoglycemics with renal failure, profound hypoglycemia may result in type II diabetic patients who cannot eat. In this setting, the administration of intravenous dextrose for 48 hours may be necessary to maintain blood glucose.",
"   </p>",
"   <p>",
"    Dialysis patients with type I disease may be extremely brittle. In some patients, for example, a single unit of insulin can make a difference between a blood glucose level of 120",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    and one of 20",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    Given the wide variations in glucose metabolism with surgery, the management of these patients may therefore be extremely difficult.",
"   </p>",
"   <p>",
"    The art of managing diabetic patients with end-stage renal disease relies upon close monitoring of blood glucose levels and a close familiarity with the behavior and insulin requirements of each patient. The measurement of preprandial and nightly blood glucose levels with periodic monitoring of serum electrolyte levels (looking for a low bicarbonate level and an increase in the serum anion gap) should therefore be performed. Obviously, urine ketones are not useful in detecting diabetic ketoacidosis (DKA) in dialysis patients; when DKA is suspected, serum ketones must be measured.",
"   </p>",
"   <p>",
"    Some additional recommendations include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous fluids should contain dextrose if the patient is fasting; insulin coverage is adjusted accordingly.",
"     </li>",
"     <li>",
"      Unless contraindicated, peritoneal dialysis patients should continue exchanges while waiting for surgery; however, their peritoneum should be drained prior to surgery, CT scan of the abdomen, or any endoscopic procedures. In these settings, insulin requirements would therefore change.",
"     </li>",
"     <li>",
"      The intelligent patient, who has had years of experience in determining the particular dose of insulin required in different settings, should be consulted to help determine the dose of insulin in the hospital.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Glucose intolerance is also a feature of uremia. As a result, non-diabetic dialysis patients may exhibit hyperglycemia in the perioperative period, especially when given glucose containing solutions, such as parenteral hyperalimentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Intravenous access",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since frequent IVs may destroy future access sites, IVs should not be routinely placed unless necessary. As an example, a peritoneal dialysis patient who is hospitalized for peritonitis and is only receiving intraperitoneal antibiotics probably does not require a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    lock IV.",
"   </p>",
"   <p>",
"    Because of the possibility of inducing subclavian stenosis, surgeons and anesthesiologists should be cautioned to avoid placing central lines in the subclavian veins. Central lines should also not be placed on the same side as the arteriovenous access.",
"   </p>",
"   <p>",
"    Knowledge of the patients' vascular anatomy, such as an occluded internal jugular, subclavian, or femoral vein, also helps the anesthesiologist establish central venous access. The use of small portable ultrasound machines to identify patent veins has decreased complications, including accidental arterial punctures and pneumothorax in high-risk patients with multiple stenotic veins.",
"   </p>",
"   <p>",
"    Displaying a sign at the patient's bedside to save the designated arm for proposed or existing accesses (avoiding needle sticks or blood pressure measurements in the arm) is important. Patients need to be taught to remind health care professionals not to use the designated arm. PICC lines should be avoided in dialysis patients unless they have a short life expectancy so as to preserve the superficial veins for future AV fistulas. Tunneled PICC lines placed in the internal jugular vein is preferred to peripherally inserted lines.",
"   </p>",
"   <p>",
"    Anesthesiologists need to care for the access intraoperatively by avoiding needle sticks, blood pressure measurements, and restraints in the access related arm. They should also keep note of the arm position so that there is no direct pressure over the access site. A stethoscope should be taped to the graft; it must be auscultated periodically by the anesthesiologist so that any immediate action can be taken if the bruit changes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     ANESTHETIC CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     General anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The metabolism of different anesthetic agents utilized in general anesthesia varies in patients with renal failure. The optimal choice of the anesthetic agent varies based upon underlying metabolism, concurrent comorbid conditions, and the surgical procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Postoperative analgesics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain relief may be provided by a variety of agents, including opiates and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Opiates",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     Fentanyl",
"    </a>",
"    appears to be the opiate of choice for dialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/34\">",
"     34",
"    </a>",
"    ]; it is well tolerated because of its short redistribution phase, the lack of active metabolites, and unchanged free fraction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By comparison,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/44/11976?source=see_link\">",
"     meperidine",
"    </a>",
"    (Demerol, pethidine) and propoxyphene should be avoided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/36\">",
"     36",
"    </a>",
"    ]. These agents are metabolized by the liver to their metabolites, normeperidine and norpropoxyphene, both of which have extremely long half-lives in dialysis patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Since normeperidine is excreted both by the liver and kidneys, the failure of either organ may cause elevated levels. Normeperidine causes myoclonic jerks, seizures, and respiratory depression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/37-39\">",
"       37-39",
"      </a>",
"      ], with central nervous system excitation directly related to elevated normeperidine to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/44/11976?source=see_link\">",
"       meperidine",
"      </a>",
"      ratios [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/40\">",
"       40",
"      </a>",
"      ]. These excitatory effects are not reversed, but may actually be enhanced, by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/24/35207?source=see_link\">",
"       naloxone",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Norpropoxyphene is a cardiotoxin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     Morphine",
"    </a>",
"    should also be used cautiously in patients with renal failure since its sedative effects are also prolonged [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/41\">",
"     41",
"    </a>",
"    ]. Morphine is metabolized by hepatic glucuronidase to morphine 3 glucuronide (M3G) and morphine 6 glucuronide (M6G) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/42\">",
"     42",
"    </a>",
"    ]. In patients with renal failure, the half-life is unchanged for morphine but it is prolonged for both M3G and M6G; these last two agents are both pharmacologically active, thereby explaining the prolonged effect of the drug in renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/43\">",
"     43",
"    </a>",
"    ]. Peritoneal dialysis does not enhance the clearance of the metabolites of morphine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Acetaminophen",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    can be used in dialysis patients without dose modification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36601/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H546579586\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dialysis patients experience increased morbidity and mortality after surgery, especially cardiac surgery. Medical management of such patients includes a preoperative evaluation, consideration of the delivery of dialysis in the period surrounding or during the surgery, intraoperative concerns (including anesthesia), and postoperative management (such as pain control). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Surgical morbidity and mortality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Baseline serum concentrations of electrolytes, glucose, blood urea nitrogen, creatinine, calcium, phosphorus, magnesium, and albumin, as well as a complete blood count and coagulation profile should be performed in all patients. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Laboratory testing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Bleeding diathesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nutritional status and dialysis adequacy should be optimized prior to the operation. Dialysis should be provided the day before surgery. Some suggest daily dialysis for a few days prior to cardiac surgery or intraoperative hemodialysis during cardiac surgery. Patients undergoing peritoneal dialysis may add an additional exchange each day for one week prior to cardiac surgery for patients on continuous ambulatory peritoneal dialysis, or an extra hour or two on the cycler each day for patients on automated peritoneal dialysis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Nutrition'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Intensive dialysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If dialysis is provided immediately prior to surgery, it is important to avoid prolonged anticoagulation, ensure that hypercalcemia and hypokalemia are not induced during the postdialysis period (by adjusting dialysate concentrations), and remove an adequate amount of total body fluid. A discussion with the surgeon and anesthesiologist regarding perioperative volume status goals is desirable in order to achieve optimal volume status prior to surgery. Special consideration must be given to the form of intradialytic anticoagulation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/14/38120?source=see_link\">",
"       \"Hemodialysis anticoagulation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lactated Ringers solution, which is commonly used postoperatively, contains potassium. Based upon the specific acid-base and electrolyte abnormalities, different fluids may be required, including specially tailored solutions. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Fluid and electrolyte issues prior to surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Coronary artery disease and myocardial dysfunction are the most common comorbidities in patients with renal failure and result in significant morbidity and mortality. A number of noninvasive methods are available to screen for the presence of coronary artery disease and myocardial dysfunction when indicated. Beta blockers may be advantageous antihypertensive agents in this setting. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Noninvasive evaluation for coronary artery disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Perioperative antibiotics should be administered in accordance with general surgical principles, including appropriate dosing adjustments for patients with renal function. The loading dose of antibiotics is usually the same in dialysis patients as in normal individuals. Since the peak tissue level of antibiotics is commonly achieved one hour after infusion, the antibiotic infusion should be completed at least one hour prior to start of surgery to minimize the risk of surgical site infection in these high-risk patients. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Perioperative antibiotics'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link\">",
"       \"Overview of control measures to prevent surgical site infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link&amp;anchor=H7#H7\">",
"       \"Overview of control measures to prevent surgical site infection\", section on 'Antimicrobial prophylaxis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      It may be difficult to maintain stable blood glucose in dialysis patients with type I disease. Close monitoring of blood glucose levels and a close familiarity with the behavior and insulin requirements of each patient are required. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Glucose metabolism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Since frequent IVs may destroy future access sites, IVs should not be routinely placed unless necessary. Because of the possibility of inducing subclavian stenosis, surgeons and anesthesiologists should be cautioned to avoid placing central lines in the subclavian veins. Central lines should also not be placed on the same side as the arteriovenous access. Anesthesiologists should avoid needle sticks, blood pressure measurements, and restraints in the access related arm. They should also keep note of the arm position so that there is no direct pressure over the access site. A stethoscope should be taped to the graft; it must be auscultated periodically by the anesthesiologist so that any immediate action can be taken if the bruit changes. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Intravenous access'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pain relief may be provided by a variety of agents, including opiates and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      .",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"       Fentanyl",
"      </a>",
"      is the opiate of choice for dialysis patients.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/44/11976?source=see_link\">",
"       Meperidine",
"      </a>",
"      (Demerol, pethidine) and propoxyphene should be avoided since their metabolites have extremely long half-lives in dialysis patients.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"       Morphine",
"      </a>",
"      should also be used cautiously since its sedative effects are prolonged in patients with renal failure. Acetaminophen can be used in dialysis patients without dose modification. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Postoperative analgesics'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/1\">",
"      Kellerman PS. Perioperative care of the renal patient. Arch Intern Med 1994; 154:1674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/2\">",
"      Pinson CW, Schuman ES, Gross GF, et al. Surgery in long-term dialysis patients. Experience with more than 300 cases. Am J Surg 1986; 151:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/3\">",
"      Deutsch E, Bernstein RC, Addonizio P, Kussmaul WG 3rd. Coronary artery bypass surgery in patients on chronic hemodialysis. A case-control study. Ann Intern Med 1989; 110:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/4\">",
"      Okada H, Sugahara S, Nakamoto H, et al. Intensive perioperative dialysis can improve the hospital mortality of haemodialysis patients undergoing cardiac surgery. Nephrol Dial Transplant 1998; 13:2713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/5\">",
"      Koyanagi T, Nishida H, Endo M, Koyanagi H. Coronary artery bypass grafting in chronic renal dialysis patients: intensive perioperative dialysis and extensive usage of arterial grafts. Eur J Cardiothorac Surg 1994; 8:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/6\">",
"      Ilson BE, Bland PS, Jorkasky DK, et al. Intraoperative versus routine hemodialysis in end-stage renal disease patients undergoing open-heart surgery. Nephron 1992; 61:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/7\">",
"      Ahmed J, Weisberg LS. Hyperkalemia in dialysis patients. Semin Dial 2001; 14:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/8\">",
"      Weisberg LS. The risk of preoperative hyperkalemia. Semin Dial 2003; 16:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/9\">",
"      Schreiber S, Korzets A, Powsner E, Wolloch Y. Surgery in chronic dialysis patients. Isr J Med Sci 1995; 31:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/10\">",
"      Brown JH, Hunt LP, Vites NP, et al. Comparative mortality from cardiovascular disease in patients with chronic renal failure. Nephrol Dial Transplant 1994; 9:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/11\">",
"      Eagle KA, Boucher CA. Cardiac risk of noncardiac surgery. N Engl J Med 1989; 321:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/12\">",
"      Eagle KA, Brundage BH, Chaitman BR, et al. Guidelines for perioperative cardiovascular evaluation for noncardiac surgery. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). J Am Coll Cardiol 1996; 27:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/13\">",
"      Le A, Wilson R, Douek K, et al. Prospective risk stratification in renal transplant candidates for cardiac death. Am J Kidney Dis 1994; 24:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/14\">",
"      Scanlon PJ, Faxon DP, Audet AM, et al. ACC/AHA guidelines for coronary angiography: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Coronary Angiography) developed in collaboration with the Society for Cardiac Angiography and Interventions. Circulation 1999; 99:2345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/15\">",
"      Welten GM, Chonchol M, Hoeks SE, et al. Beta-blockers improve outcomes in kidney disease patients having noncardiac vascular surgery. Kidney Int 2007; 72:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/16\">",
"      Holley JL, Fenton RA, Arthur RS. Thallium stress testing does not predict cardiovascular risk in diabetic patients with end-stage renal disease undergoing cadaveric renal transplantation. Am J Med 1991; 90:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/17\">",
"      Brown KA, Rimmer J, Haisch C. Noninvasive cardiac risk stratification of diabetic and nondiabetic uremic renal allograft candidates using dipyridamole-thallium-201 imaging and radionuclide ventriculography. Am J Cardiol 1989; 64:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/18\">",
"      Camp AD, Garvin PJ, Hoff J, et al. Prognostic value of intravenous dipyridamole thallium imaging in patients with diabetes mellitus considered for renal transplantation. Am J Cardiol 1990; 65:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/19\">",
"      Dahan M, Viron BM, Faraggi M, et al. Diagnostic accuracy and prognostic value of combined dipyridamole-exercise thallium imaging in hemodialysis patients. Kidney Int 1998; 54:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/20\">",
"      Reis G, Marcovitz PA, Leichtman AB, et al. Usefulness of dobutamine stress echocardiography in detecting coronary artery disease in end-stage renal disease. Am J Cardiol 1995; 75:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/21\">",
"      Garcia-Canton, C, Culegras, C, Hernandez-Britz, MJ, et al. Dobutamine stress echocardiography and stress 99 m technetium SPECT imaging in the assessment of coronary artery disease in kidney transplant candidates. (Abstract). J Am Soc Nephrol 1998; 9:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/22\">",
"      Remuzzi G. Bleeding in renal failure. Lancet 1988; 1:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/23\">",
"      Pivalizza EG, Abramson DC, Harvey A. Perioperative hypercoagulability in uremic patients: a viscoelastic study. J Clin Anesth 1997; 9:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/24\">",
"      Steiner RW, Coggins C, Carvalho AC. Bleeding time in uremia: a useful test to assess clinical bleeding. Am J Hematol 1979; 7:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/25\">",
"      Liu YK, Goldstein DM, Arora K, et al. Thigh bleeding time as a valid indicator of hemostatic competency during surgical treatment of patients with advanced renal disease. Surg Gynecol Obstet 1991; 172:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/26\">",
"      Livio M, Gotti E, Marchesi D, et al. Uraemic bleeding: role of anaemia and beneficial effect of red cell transfusions. Lancet 1982; 2:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/27\">",
"      Janson PA, Jubelirer SJ, Weinstein MJ, Deykin D. Treatment of the bleeding tendency in uremia with cryoprecipitate. N Engl J Med 1980; 303:1318.",
"     </a>",
"    </li>",
"    <li>",
"     Aronoff, GR, Berns, JS, Brier, ME, et al. Drug prescribing in renal failure: Dosing guidelines for adults, 4th Ed, American College of Physicians, Philadelphia, PA 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/29\">",
"      Zibari GB, Gadallah MF, Landreneau M, et al. Preoperative vancomycin prophylaxis decreases incidence of postoperative hemodialysis vascular access infections. Am J Kidney Dis 1997; 30:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/30\">",
"      Sardegna KM, Beck AM, Strife CF. Evaluation of perioperative antibiotics at the time of dialysis catheter placement. Pediatr Nephrol 1998; 12:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/31\">",
"      Golper TA, Brier ME, Bunke M, et al. Risk factors for peritonitis in long-term peritoneal dialysis: the Network 9 peritonitis and catheter survival studies. Academic Subcommittee of the Steering Committee of the Network 9 Peritonitis and Catheter Survival Studies. Am J Kidney Dis 1996; 28:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/32\">",
"      Lye WC, Lee EJ, Tan CC. Prophylactic antibiotics in the insertion of Tenckhoff catheters. Scand J Urol Nephrol 1992; 26:177.",
"     </a>",
"    </li>",
"    <li>",
"     US Renal Data System, USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/34\">",
"      Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage 2004; 28:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/35\">",
"      Sear JW. Kidney transplants: induction and analgesic agents. Int Anesthesiol Clin 1995; 33:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/36\">",
"      Kurella M, Bennett WM, Chertow GM. Analgesia in patients with ESRD: a review of available evidence. Am J Kidney Dis 2003; 42:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/37\">",
"      Geller RJ. Meperidine in patient-controlled analgesia: a near-fatal mishap. Anesth Analg 1993; 76:655.",
"     </a>",
"    </li>",
"    <li>",
"     Gillman, AG, Rall, TW, Nies, AS, et al. Goodman &amp; Gillman's, The pharmacologic basis of therapeutics, 8th ed, Pergamon Press, New York 1990. p. 504.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/39\">",
"      Szeto HH, Inturrisi CE, Houde R, et al. Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure of cancer. Ann Intern Med 1977; 86:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/40\">",
"      Kaiko RF, Foley KM, Grabinski PY, et al. Central nervous system excitatory effects of meperidine in cancer patients. Ann Neurol 1983; 13:180.",
"     </a>",
"    </li>",
"    <li>",
"     Bansal, VK, Vertuno, LL. In: Handbook of Dialysis, 2nd Edition, Daugirdas JR, Ing, TS (Eds), Little Brown and Co 1994. p. 551.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/42\">",
"      Peterson GM, Randall CT, Paterson J. Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: relationship to renal function and route of administration. Eur J Clin Pharmacol 1990; 38:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/43\">",
"      Chauvin M, Sandouk P, Scherrmann JM, et al. Morphine pharmacokinetics in renal failure. Anesthesiology 1987; 66:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36601/abstract/44\">",
"      Hanna MH, D'Costa F, Peat SJ, et al. Morphine-6-glucuronide disposition in renal impairment. Br J Anaesth 1993; 70:511.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1899 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-210.101.131.232-33503A3141-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_47_36601=[""].join("\n");
var outline_f35_47_36601=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H546579586\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SURGICAL MORBIDITY AND MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MEDICAL MANAGEMENT OF THE DIALYSIS PATIENT UNDERGOING SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Anemia status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Intensive dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Fluid and electrolyte issues prior to surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Hyperkalemia and emergency surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hypotension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cardiovascular evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Clinical evaluation of cardiac risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Noninvasive evaluation for coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Noninvasive evaluation for myocardial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Emergency surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Bleeding diathesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Heparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Perioperative antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Glucose metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Intravenous access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      ANESTHETIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      General anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Postoperative analgesics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Opiates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Acetaminophen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H546579586\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1899\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1899|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/22/35179\" title=\"table 1\">",
"      Clinical predictors of increased perioperative risk among pts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/58/1962?source=related_link\">",
"      Adequacy of peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/3/5178?source=related_link\">",
"      Approach to the adult patient with a bleeding diathesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/2/15399?source=related_link\">",
"      Assessment of nutritional status in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/49/33559?source=related_link\">",
"      Clinical manifestations and diagnosis of coronary heart disease in end-stage renal disease (dialysis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36810?source=related_link\">",
"      Estimation of cardiac risk prior to noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/14/38120?source=related_link\">",
"      Hemodialysis anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/32/31240?source=related_link\">",
"      Hemodynamic instability during hemodialysis: Overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/46/20202?source=related_link\">",
"      Hypertension in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/14/6378?source=related_link\">",
"      Kt/V and the adequacy of hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/21/11610?source=related_link\">",
"      Noninvasive methods for measurement of left ventricular systolic function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/3/9274?source=related_link\">",
"      Pathogenesis and treatment of malnutrition in maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/45/40666?source=related_link\">",
"      Perioperative medication management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/63/6136?source=related_link\">",
"      Placement and maintenance of the peritoneal dialysis catheter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/30/10727?source=related_link\">",
"      Platelet dysfunction in uremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/17/277?source=related_link\">",
"      Protein catabolic rate in maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/58/22440?source=related_link\">",
"      Seizures in patients undergoing hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/30/44520?source=related_link\">",
"      Selecting the optimal cardiac stress test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/54/17258?source=related_link\">",
"      Treatment and prevention of hyperkalemia in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_47_36602="Sentinel lymph node dissection for breast cancer: Indications and outcomes";
var content_f35_47_36602=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sentinel lymph node dissection for breast cancer: Indications and outcomes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/47/36602/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/47/36602/contributors\">",
"     Seth P Harlow, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/47/36602/contributors\">",
"     Donald L Weaver, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/47/36602/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/47/36602/contributors\">",
"     Anees B Chagpar, MD, MSc, MA, MPH, FACS, FRCS(C)",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/47/36602/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/47/36602/contributors\">",
"     Lori J Pierce, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/47/36602/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/47/36602/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/47/36602/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The status of the axillary lymph nodes is one of the most important prognostic factors in women with early stage breast cancer. Histologic examination of lymph nodes is the most accurate method for assessing spread of disease to these nodes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/52/42825?source=see_link\">",
"     \"Management of the regional lymph nodes in breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Axillary lymph node dissection (ALND) has traditionally been a routine component of the management of early breast cancer. The benefits of ALND include its impact on disease control (ie, axillary recurrence and survival), its prognostic value, and its role in treatment selection. However, the anatomic disruption caused by ALND may result in lymphedema, nerve injury, and shoulder dysfunction, which compromise functionality and quality of life.",
"   </p>",
"   <p>",
"    ALND remains the standard approach for women who have clinically palpable axillary nodes or positive nodes confirmed by methods such as ultrasound guided fine needle aspiration. For patients who have clinically negative axillary lymph nodes, sentinel lymph node dissection (SLND) is a method of staging the axilla with less morbidity than ALND.",
"   </p>",
"   <p>",
"    Indications for and outcomes of SLND will be reviewed here. The technique of SLND in patients with breast cancer is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/52/20296?source=see_link\">",
"     \"Sentinel lymph node biopsy in breast cancer: Techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2642382\">",
"    <span class=\"h1\">",
"     DEVELOPMENT AND VALIDATION OF THE SLNB TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sentinel lymph node (SLN) technique is based upon the observation that tumor cells migrating from a primary tumor metastasize to one or a few lymph nodes (LNs) before involving other LNs. Injection of vital blue dye",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiolabeled colloid around the area of the tumor permits identification of a SLN in the majority of patients, and its status accurately predicts the status of the remaining regional LNs (",
"    <a class=\"graphic graphic_picture graphicRef61541 \" href=\"mobipreview.htm?21/11/21687\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74338 \" href=\"mobipreview.htm?43/18/44326\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52790 \" href=\"mobipreview.htm?15/24/15748\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59469 \" href=\"mobipreview.htm?24/32/25088\">",
"     image 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/52/20296?source=see_link\">",
"     \"Sentinel lymph node biopsy in breast cancer: Techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with clinically node negative breast cancer, SLND identifies patients without axillary node involvement, thereby obviating the need for more extensive surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/1\">",
"     1",
"    </a>",
"    ]. Several studies have shown that the risk of arm morbidity, particularly lymphedema, sensory loss, and shoulder abduction deficits, is significantly less for SLND than with standard axillary dissection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/2-8\">",
"     2-8",
"    </a>",
"    ]. As an example, the risk of lymphedema after 12 months was reported as 2 percent after SLND alone as compared with 13 percent after SLND with axillary lymph node dissection (ALND) in the American College of Surgeons Oncology Group (ACOSOG) Z-0011 trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/2\">",
"     2",
"    </a>",
"    ]. Similarly, in the NSABP B-32 trial, at 36 months follow-up, patients who had an SLND alone were less likely to develop lymphedema than patients who had an SLND plus a completion ALND (8 percent as compared to 14 percent respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/52/1866?source=see_link\">",
"     \"Clinical manifestations and diagnosis of lymphedema\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most surgeons and major cancer centers have adopted SLND as a standard means of axillary nodal assessment. In a study of over 490,000 women with early breast cancer from the National Cancer Database, use of SLND increased from 27 to 66 percent between 1998 and 2005 in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/9\">",
"     9",
"    </a>",
"    ]. Similar trends have been reported from Canada and the United Kingdom [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. SLND is endorsed as an alternative to ALND for the diagnosis of axillary metastases in patients with clinically node-negative early breast cancer in guidelines from the American Society of Clinical Oncology (ASCO) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/12\">",
"     12",
"    </a>",
"    ], the International Expert Consensus Panel on the Primary Therapy of Early Breast Cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/13\">",
"     13",
"    </a>",
"    ], and others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite variability in selection criteria and technique, a SLN is consistently identified in approximately 96 percent of cases, and predicts the status of the remaining axillary LNs in &ge;95 percent of cases in most series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/1,16\">",
"     1,16",
"    </a>",
"    ]. The false negative rate of SLND was originally reported as 5 to 10 percent (sensitivity 90 to 95 percent), but lower rates are attainable by experienced surgeons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/1,17\">",
"     1,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The greatest concern with SLND is the potential of a false negative result, which could increase the potential for axillary recurrence. However, despite the approximately 5 to 10 percent false negative rate with SLND found in studies in which completion ALND has been done, several series suggest that axillary recurrence rates are low after a negative SLND alone in early stage breast cancer (range 0 to 4.5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/17-27\">",
"     17-27",
"    </a>",
"    ]. The details of key trials validating the SLND are described below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A landmark multicenter study of 443 patients with early breast cancer demonstrated that the SLND technique could be learned and successfully applied by a diverse group of surgeons spanning private and academic practice [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. All patients underwent SLND using radiolabeled colloid followed by completion ALND. At least one SLN was identified in 98 percent of cases and the predictive value of a negative SLN was 96 percent, with a false negative rate of 11 percent (sensitivity 88 percent). More intensive pathologic evaluation of the nodes in false negative cases with deeper sectioning of the sentinel node and immunohistochemical staining increased the yield of occult metastases and led to an overall case conversion rate of 10.3 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A systematic review, performed by the ASCO expert guidelines panel, included 69 eligible trials of SLND in early stage breast cancer, representing 8059 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/12,31\">",
"       12,31",
"      </a>",
"      ]. The SLN was identified using radiocolloid, blue dye, or both. SLN identification was successful in 95 percent of patients. The false negative rate was 7.3 percent (range 0 to 29 percent). The combination of radiocolloid and blue dye resulted in a significantly higher success rate in SLN mapping with a lower false negative rate as compared to blue dye alone.",
"     </li>",
"     <li>",
"      The NSABP B-32 trial, published after the systematic review, enrolled 5611 breast cancer patients with clinically negative nodes and compared SLND followed by ALND versus SLND followed by ALND only if the SLN was positive [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]. Lymphatic mapping was successful in 97 percent, and the false negative rate was 9.8 percent. No significant differences were observed in regional control, overall survival (OS), or disease free survival (DFS) between the groups at a median follow-up of almost eight years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/34,35\">",
"       34,35",
"      </a>",
"      ]. Similar findings were reported from the KiSS study (German Clinical Interdisciplinary Sentinel Study), a trial of 1182 patients randomized to SLND followed by ALND versus SLND followed by ALND only if the SLN was positive [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;SLND should be performed in most women with clinically node negative invasive or microinvasive breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/15\">",
"     15",
"    </a>",
"    ]. SLND can be omitted if the nodal information will not affect adjuvant treatment decisions. As an example, women &ge;70 years of age who have a small (&lt;2 cm) estrogen receptor-positive tumor and a clinically uninvolved axilla may be treated without a SLND. The management of early breast cancer in older women is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/58/13226?source=see_link&amp;anchor=H14#H14\">",
"     \"General principles on the treatment of early stage and locally advanced breast cancer in older women\", section on 'Management of the axilla'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SLND should be performed in women with extensive ductal carcinoma in situ (DCIS), who are undergoing mastectomy. A SLND will not be possible after mastectomy if invasive disease is found on final pathology, necessitating an axillary dissection for staging purposes. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Ductal carcinoma in situ'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    When a SLND is not successful or when clinically suspicious nodes are encountered in the axilla the surgeon should perform an axillary dissection for staging purposes and to ensure locoregional control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/52/42825?source=see_link\">",
"     \"Management of the regional lymph nodes in breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     THE ROLE OF ULTRASOUND IN SENTINEL NODE EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with clinically suspicious lymph nodes, preoperative axillary ultrasound (US) with fine needle aspiration (FNA) or core biopsy of suspicious areas provides a means to identify patients who have positive nodes, and thus may need axillary lymph node dissection (ALND) rather than a SLND [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/37-50\">",
"     37-50",
"    </a>",
"    ]. As an example, in a series of 653 consecutive patients, the preoperative diagnosis rate of axillary disease was 23 percent using axillary US and FNA, thereby avoiding the need for a second operation in 150 women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/50\">",
"     50",
"    </a>",
"    ]. The efficacy of this approach is somewhat variable between centers because the accuracy of US examination is operator dependent (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67261 \" href=\"mobipreview.htm?15/19/15664\">",
"     image 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82343 \" href=\"mobipreview.htm?43/23/44403\">",
"     image 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54435 \" href=\"mobipreview.htm?25/26/26019\">",
"     image 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/36/24138?source=see_link\">",
"     \"Diagnostic evaluation of women with suspected breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/59/24504?source=see_link\">",
"     \"Breast biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF SLN METASTASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 40 percent of patients with a positive sentinel lymph node (SLN) will be found to have residual disease in the axilla [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/12,28,32,51-58\">",
"     12,28,32,51-58",
"    </a>",
"    ]. SLN metastases are categorized as isolated tumor cells, micrometastases, or macrometastases, depending upon the size of the largest tumor deposit in the sentinel node. Each of these is discussed below. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6264723\">",
"    <span class=\"h2\">",
"     Isolated tumor cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;The seventh edition of the American Joint Committee on Cancer (AJCC) tumor node metastasis (TNM) staging system for breast cancer includes a stringent classification for lymph node findings of isolated tumor cell clusters and single cells. Small clusters of cells not greater than 0.2 mm, or nonconfluent or nearly confluent clusters of cells not exceeding 200 cells in a single histologic lymph node cross section, are classified as isolated tumor cells and are considered prognostically similar to node negative patients. Malignant cells in regional lymph node(s) no greater than 0.2 mm are designated as pN0(i+). Isolated tumor cells are not considered an indication for further axillary surgery, radiation treatment, or adjuvant systemic therapy. The finding of isolated tumor cells in lymphatics as a result of iatrogenic displacement from core biopsy procedures has been observed and is not considered to be clinically significant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/59-62\">",
"     59-62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/45/24278?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging classification for breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1583503\">",
"    <span class=\"h2\">",
"     Micrometastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;SLND allows the pathologist to perform a more detailed study of one or a few LNs that are most likely to contain metastases, compared to the 15 to 25 LNs obtained with ALND. This has the potential to improve staging accuracy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/63\">",
"     63",
"    </a>",
"    ], but has led to an increase in the identification of micrometastatic nodal involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/64\">",
"     64",
"    </a>",
"    ]. For this reason, there is a separate designation of pN1mi (&gt;0.2 mm and no greater than 2.0 mm) to indicate micrometastases alone. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/45/24278?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging classification for breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although patients with micrometastases are considered node positive and it seems intuitive that the finding of axillary micrometastases should worsen prognosis, most studies show no change or only a small reduction in patient survival compared with those without micrometastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/65-71\">",
"     65-71",
"    </a>",
"    ]. However, some analyses suggest a negative impact of micrometastases on breast cancer outcomes, including regional recurrence rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/72-79\">",
"     72-79",
"    </a>",
"    ]. In a retrospective review of patients undergoing a SLND without a completion axillary node dissection, patients with micrometastatic disease (n = 141) had a significantly higher five-year regional recurrence rate compared with patients with isolated cancer cells (n = 345) and SLN negative findings (n = 732) (5.6 versus 2.0 versus 2.3 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/79\">",
"     79",
"    </a>",
"    ]. Patients with micrometastatic disease in SLN without a completion axillary node dissection also had a significantly higher rate of recurrence compared with patients with micrometastatic disease and a completion axillary dissection (n = 887) (5.6 versus 1.0 percent, hazard ratio [HR] 4.39, 95% CI 1.46-13.24). There was no significant difference based upon axillary completion in the other two cohorts. There were no regional recurrences if the axilla was treated with radiation therapy for patients with isolated cancer cells (n = 54) or micrometastatic disease (n = 94). Patients with grade 3 breast cancer (HR 5.05, 1.26-16.62) and negative hormone receptor status (HR 4.96, 1.48-16.62) were significantly more likely to recur.",
"   </p>",
"   <p>",
"    Pathologic evaluation for occult metastases in a randomized trial of 3887 women who underwent SLND alone or SLND plus ALND for invasive breast cancer detected occult metastases in 16 percent of patients (isolated tumor cell clusters in 11 percent, micrometastases in 4 percent, and macrometastases in 0.4 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/80\">",
"     80",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Occult metastases were an independent adverse prognostic factor with an increased risk of distant disease and death.",
"     </li>",
"     <li>",
"      Smaller metastases had less of an adverse effect on outcomes than larger metastases, and the risk associated with isolated tumor cell clusters was less than the risk associated with micrometastases.",
"     </li>",
"     <li>",
"      At five years, the differences in outcomes for patients with and without occult metastases were statistically significant but relatively small with respect to overall survival (95 versus 96 percent), disease free survival (86 versus 89 percent), and distant disease free interval (90 versus 92 percent).",
"     </li>",
"     <li>",
"      The presence of occult metastases was not a discriminatory predictive factor; 85 percent of women with occult metastases were alive without recurrent breast cancer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is debate about the prognostic value of the size of the SLN micrometastases (&le;0.2 mm versus larger) in predicting the likelihood and significance of involvement of axillary non-SLNs (",
"    <a class=\"graphic graphic_table graphicRef78108 \" href=\"mobipreview.htm?4/61/5085\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/81-85\">",
"     81-85",
"    </a>",
"    ]. Although guidelines from ASCO and NCCN recommend that routine completion ALND be carried out for micrometastases detected on SLND with standard hematoxylin and eosin (H&amp;E) examination, this practice is now being questioned for women with less than three positive lymph nodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/12,15\">",
"     12,15",
"    </a>",
"    ]. This is discussed in detail below. (See",
"    <a class=\"local\" href=\"#H5456194\">",
"     'When should completion axillary dissection be performed?'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6264783\">",
"    <span class=\"h2\">",
"     Macrometastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2005 American Society of Clinical Oncology (ASCO) guidelines and 2010 National Comprehensive Cancer Network (NCCN) guidelines recommend that routine completion ALND be carried out for patients with SLND macrometastases (&ge;2 mm) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/12,15\">",
"     12,15",
"    </a>",
"    ]. However, the indications for a completion ALND in patients with &lt;3 positive sentinel nodes is the subject of controversy. This is discussed in detail below. (See",
"    <a class=\"local\" href=\"#H5456194\">",
"     'When should completion axillary dissection be performed?'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6170711\">",
"    <span class=\"h3\">",
"     Role of IHC and RT-PCR in sentinel node evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occult micrometastases refers to nodal metastases that are not seen on initial hematoxylin and eosin (H&amp;E) examination but are detected subsequently by additional level or by immunohistochemistry (IHC) or reverse transcriptase polymerase chain reaction (RT-PCR). The significance of occult micrometastases in terms of surgical management and patient outcome appears to be negligible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/78,86-88\">",
"     78,86-88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Results from the American College of Surgeons Oncology Group (ACOSOG) study Z0010, a prospective multicenter study of 5210 patients with almost eight-year follow-up, confirm that IHC-detected metastases have no significant impact on overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/88\">",
"     88",
"    </a>",
"    ]. Thus, routine IHC or PCR is not recommended for the evaluation of SLNs in guidelines published by ASCO, NCCN, and others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/12,15,89\">",
"     12,15,89",
"    </a>",
"    ]. Histologically negative nodes that are IHC or RT-PCR-positive are classified as pN0 disease in the TNM staging system for breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/45/24278?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging classification for breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1583667\">",
"    <span class=\"h4\">",
"     Role of IHC in invasive lobular carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although routine IHC staining with cytokeratin is not indicated for most breast cancers, it can be helpful for examination of the sentinel nodes in patients with invasive lobular carcinoma since the morphology of lobular cancer can be difficult to detect on H&amp;E of axillary lymph nodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. In general, IHC should be used to definitively diagnose an area that is suspicious for, but not diagnostic of, lymph node metastases on H&amp;E rather than as a routine method of evaluating nodes in cases of invasive lobular cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5456194\">",
"    <span class=\"h2\">",
"     When should completion axillary dissection be performed?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for completion axillary lymph node dissection (ALND) in women with clinically node negative T1 or T2 tumors is dependent upon the SLND findings. The indications for a completion axillary dissection are evolving [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is general acceptance for the following approaches:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a negative sentinel lymph node biopsy (SLND), completion ALND is",
"      <strong>",
"       not",
"      </strong>",
"      indicated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/35,93\">",
"       35,93",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with a SLND showing isolated tumor cells only are considered node negative for prognostic purposes and completion ALND is",
"      <strong>",
"       not",
"      </strong>",
"      indicated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For patients with a positive SLND showing micrometastases or macrometastases in",
"      <strong>",
"       three or more nodes",
"      </strong>",
"      , detected with standard hematoxylin and eosin (H&amp;E) examination, completion ALND is recommended for staging purposes and to ensure local control [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/12,15\">",
"       12,15",
"      </a>",
"      ]. The timing of the procedure (ie, immediate [one operation] versus delayed [two separate operations]) does not seem to affect the total lymph node yield or the rate of long-term complications (particularly lymphedema) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/94\">",
"       94",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The need for a completion ALND in patients with a positive SLND showing micrometastases or macrometastases in",
"    <strong>",
"     less than three nodes",
"    </strong>",
"    has been questioned [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/95\">",
"     95",
"    </a>",
"    ]. The SLN is the sole tumor-bearing node in up to 60 percent of cases overall, and in almost 90 percent of patients who harbor only micrometastatic disease. These observations have led to speculation that completion ALND may not be necessary in selected patients with a positive SLND in less than three nodes because the need for systemic therapy is established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/28,51-55,96\">",
"     28,51-55,96",
"    </a>",
"    ] and the risk of an axillary recurrence appears to be low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/18,97-99\">",
"     18,97-99",
"    </a>",
"    ]. In a retrospective review of 30 studies including 7151 women with a positive SLN not undergoing a completion ALND with a median follow-up of 45 months, the axillary recurrence rate was 0.3 percent for patients with micrometastases and 0.7 percent for patients with macrometastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13373789\">",
"    <span class=\"h3\">",
"     ACOSOG Z-0011 trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American College of Surgeons Oncology Group (ACOSOG) study Z0011 (ACOSOG Z-0011) trial was designed to address the need for completion ALND for patients with T1 or T2 tumors that were clinically node negative and had less than three positive sentinel nodes; all patients were treated with radiation to the breast [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/2,101,102\">",
"     2,101,102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pertinent results of the trial included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At a median follow-up of 6.3 years, there were no significant differences in survival or locoregional recurrence between the SLND plus ALND group versus the SLND alone group.",
"     </li>",
"     <li>",
"      The five-year overall survival was similar whether women were treated with SLND plus ALND or with SLND alone (91.9 versus 92.5 percent, respectively) (HR 0.79, 90% CI 0.56-1.10).",
"     </li>",
"     <li>",
"      The five-year disease-free survival was also similar between the two arms (82.2 versus 83.9 percent, respectively).",
"     </li>",
"     <li>",
"      Recurrence rates in the ipsilateral axilla were similar between the two arms with four recurrences (0.9 percent) in the SLND alone arm compared with two recurrences (0.5 percent) in the SLND plus ALND arm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ACOSOG Z-0011 trial was criticized for a number of performance deficiencies, including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/103,104\">",
"     103,104",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Target accrual for ACOSOG Z-0011 study was 1900 patients. The study closed prematurely because of low accrual and low event rate after enrolling 436 patients in the SLND alone arm and 420 in the SLND plus ALND arm.",
"     </li>",
"     <li>",
"      The trial was not adequately powered to meet the predetermined statistical survival primary endpoint due to low accrual.",
"     </li>",
"     <li>",
"      Eleven patients assigned to the SLND only arm did have an ALND and 32 patients assigned to the SLND plus ALND arm did not have an ALND.",
"     </li>",
"     <li>",
"      Almost 20 percent of patients were lost to follow-up and 7 percent of patients in the SLND arm were found to be node negative compared with 1 percent of the ALND arm.",
"     </li>",
"     <li>",
"      There was no breakdown of the numbers of patients with isolated tumor cell clusters, micrometastases or macrometastases in the two arms.",
"     </li>",
"     <li>",
"      The majority of patients had T1 (almost 70 percent), hormone receptor positive tumors (85 percent). Estrogen receptor status and adjuvant systemic therapy were independent predictors of survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon the apparent lack of regional benefit and low risk of events in this trial, completion ALND may not be necessary for all women with T1 tumors that are clinically node negative, with less than three positive SLNs, who will be treated with whole breast radiation, particularly in women with estrogen receptor positive tumors. When completion ALND is omitted in patients with a positive SLND, whole breast radiotherapy is indicated. If partial breast radiation is planned, completion ALND should be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13373796\">",
"    <span class=\"h3\">",
"     IBCSG 23-01 trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Breast Cancer Study Group trial 23-01 (IBCSG 23-01) randomized patients with SLN micrometastases (&lt;2 mm) and primary tumors &lt;5 cm in size to either completion ALND or no additional axillary surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/105\">",
"     105",
"    </a>",
"    ]. The primary end-points included five-year disease-free survival (DFS) and overall survival (OS) rates. The target accrual of this trial was 1960 patients; however, the trial closed early with 931 patients accrued and is underpowered. Only one or two sentinel nodes were positive for 85 percent of patients. In addition, no patient had metastases greater than 2 mm in size and 67 percent had less than 1.0 mm of microscopic disease in the sentinel node.",
"   </p>",
"   <p>",
"    The pertinent results of the trial are reported only in abstract form and include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With a median follow-up of 49 months, there was no significant difference in DFS rate for patients treated with an ALND compared with those treated with a SLND (87 versus 92 percent).",
"     </li>",
"     <li>",
"      There was no significant difference in OS rate for patients treated with an ALND compared with those treated with a SLND (97.6 versus 98.0 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment regimen included:",
"    <br/>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Breast conserving surgery was performed for 90 percent; the remaining 10 percent underwent a total mastectomy.",
"     </li>",
"     <li>",
"      Adjuvant radiation therapy was administered in 89 percent of patients undergoing an ALND and 92 percent of patients undergoing a SLND only.",
"     </li>",
"     <li>",
"      Adjuvant anti-estrogen hormone therapy was administered in 63 percent of patients undergoing an ALND and 67 percent of patients undergoing a SLND.",
"     </li>",
"     <li>",
"      Chemotherapy was administered to 7 percent of patients undergoing an ALND and 9 percent of patients undergoing a SLND.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The results of this trial, when considered in the context of the ACOSOG Z0011 trial, offer additional support to the concept that a subset of patients with metastases to sentinel nodes may in fact do well with SLND alone as compared with a completion ALND. However, the data are derived from studies that are underpowered and have relatively short follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13373821\">",
"    <span class=\"h3\">",
"     NCIC-CTG MA. 20 trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) MA.20 trial randomized 1832 node positive or high-risk node negative breast cancer patients treated with breast conserving surgery and ALND to whole breast irradiation (WBI, 50Gy in 25 fractions",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    boost irradiation) alone or WBI plus regional nodal irradiation (RNI, 45Gy in 25 fractions) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/106\">",
"     106",
"    </a>",
"    ]. RNI was administered to the internal mammary, supraclavicular, and high axillary lymph nodes. The mean follow-up was 62 months.",
"   </p>",
"   <p>",
"    It is not certain that the same benefit of RNI would be seen in patients treated with SLN biopsy alone as compared with those getting a complete ALND [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Characteristics of the study population included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Node negative breast cancer in 10 percent",
"     </li>",
"     <li>",
"      One to three positive ALN in 85 percent",
"     </li>",
"     <li>",
"      Greater than 4 ALN positive in 5 percent",
"     </li>",
"     <li>",
"      Adjuvant chemotherapy administered to 91 percent",
"     </li>",
"     <li>",
"      Adjuvant endocrine therapy administered to 71 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pertinent results of the trial reported only in abstract form include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/107\">",
"     107",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients treated with WBI and RNI had a significantly improved risk of isolated locoregional five-year DFS compared with patients treated with WBI alone (96.8 versus 94.5 percent, hazard ratio [HR] 0.59).",
"     </li>",
"     <li>",
"      Patients treated with WBI and RNI had a significantly improved risk of distant five-year DFS compared with patients treated with WBI alone (92.4 versus 87.0 percent, HR 0.64).",
"     </li>",
"     <li>",
"      Patients treated with WBI and RNI had a significantly improved risk of five-year OS compared with patients treated with WBI alone (92.3 versus 90.7 percent, HR 0.76).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Complications included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Grade 2 or greater pneumonitis was significantly more common in patients treated with WBI and RNI (1.3 versus 0.2 percent).",
"     </li>",
"     <li>",
"      Upper extremity lymphedema was significantly more common in patients treated with WBI and RNI (7.3 versus 4.1 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The results of this trial are preliminary; however, the findings are no less compelling than those of the ACOSOG Z0011 and IBCSG 23-01 trials. While the benefit may be strictly due to the additional axillary radiation, it is not certain that RNI would benefit patients treated with SLND alone as compared with those getting a complete ALND. Additional follow-up is needed before the results of this trial can be used to recommend RNI as standard treatment for node positive patients. The additional morbidity (eg, extremity lymphedema) and its impact on quality of life will also need to be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13373803\">",
"    <span class=\"h3\">",
"     NCCN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Comprehensive Cancer Network (NCCN) has not changed their guidelines and continues to recommend completion ALND for all women with positive sentinel nodes until additional randomized trial results are available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/15\">",
"     15",
"    </a>",
"    ]. However, a distinction can be made between isolated tumor cells, micrometastases, and macrometastases, in terms of clinical management, especially because at least 22 percent misclassification of sentinel node metastases has been demonstrated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/108\">",
"     108",
"    </a>",
"    ]. In light of this, omission of the ALND can be considered if the tumor burden appears low (eg, in cases with isolated tumor cells or micrometastases) when whole breast radiation with high axillary tangents is planned. Additional results are pending from two ongoing randomized trials studying the benefit of ALND for clinically node negative women with positive SLNs: the EORTC 10981-22023 AMAROS trial; and Trial 23-01 of the International Breast Cancer Study Group (IBCSG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/16,109\">",
"     16,109",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/52/42825?source=see_link&amp;anchor=H19#H19\">",
"     \"Management of the regional lymph nodes in breast cancer\", section on 'Axillary radiation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13373810\">",
"    <span class=\"h3\">",
"     Mastectomy procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who are having mastectomy rather than breast conserving therapy should be counseled that they will need completion ALND if the SLND is positive, in order to determine the need for postmastectomy radiation. In addition, patients having a mastectomy and those who underwent neoadjuvant chemotherapy were excluded from the ACOSOG Z-011 trial, and therefore results of this trial could not be extrapolated to these patients. &nbsp;",
"   </p>",
"   <p>",
"    In some cases it may be preferable to perform the sentinel node biopsy as a separate procedure before the mastectomy, especially if reconstruction is desired, so that the proper sequencing of reconstruction and radiation can be arranged. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/3/41017?source=see_link\">",
"     \"Postmastectomy chest wall irradiation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/29/39386?source=see_link&amp;anchor=H2464163#H2464163\">",
"     \"Breast reconstruction in women with breast cancer\", section on 'Radiation therapy and reconstruction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Predictive nomograms",
"    </span>",
"    &nbsp;&mdash;&nbsp;SLND followed by a completion ALND results in significantly greater arm morbidity than SLND alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/2\">",
"     2",
"    </a>",
"    ]. Because the majority of patients with SLND metastases will not have additional positive nodes on completion ALND, several predictive nomograms for estimating the risk of additional positive nodes have been developed in an effort to spare women from unnecessary and potentially morbid surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/20,110-116\">",
"     20,110-116",
"    </a>",
"    ]. These nomograms include both clinical and pathologic features, such as the size",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    number of the SLN metastases, extranodal extension, the size",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    presence of lymphovascular invasion in the primary tumor, and the size of the metastatic disease in the SLN as a continuous variable from a prospective cohort of 561 patients with positive SLN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/116\">",
"     116",
"    </a>",
"    ]. A retrospective analysis of 319 patients with a positive SLND who underwent completion axillary dissection compared the performance of four different nomograms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/112\">",
"     112",
"    </a>",
"    ]. None of the nomograms was sufficiently reliable for clinical use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SLNB IN SPECIAL CIRCUMSTANCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sentinel lymph node biopsy (SLND) remains controversial in selected clinical settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Male breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of published studies of SLND for breast cancer are in women. Data are limited in men with breast cancer (MBC), because it is uncommon. A retrospective study of 30 men with breast cancer reported a 100 percent SLND identification rate and a false negative rate of 0 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/117\">",
"     117",
"    </a>",
"    ]. Prospective studies establishing the sensitivity and specificity of SLND in MBC have not been carried out. However, the principles guiding SLND in women appear to apply to men.",
"   </p>",
"   <p>",
"    Due to the limited amount of data, the 2005 American Society of Clinical Oncology (ASCO) guidelines on SLND did not make a specific recommendation about the use of SLND in MBC, although it was deemed \"acceptable\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/12\">",
"     12",
"    </a>",
"    ]. This topic is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/36/26186?source=see_link&amp;anchor=H21#H21\">",
"     \"Breast cancer in men\", section on 'Management of the regional nodes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Locally advanced and inflammatory breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies have restricted SLND to T1 or T2 breast cancers &lt;5 cm in size, since larger tumors have a higher likelihood of positive axillary nodes. However, some studies have shown that SLND is accurate in patients with T3 tumors and clinically negative axillae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/118,119\">",
"     118,119",
"    </a>",
"    ]. Thus, many clinicians do not recognize large breast tumors as a contraindication to SLN dissection, as long as the axilla is clinically negative.",
"   </p>",
"   <p>",
"    However, patients with T4 tumors (locally advanced) or inflammatory breast cancer are not considered candidates for SLND [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/120,121\">",
"     120,121",
"    </a>",
"    ]. The false negative rate is high in patients with inflammatory breast cancer, presumably because of the presence of partially obstructed, functionally abnormal subdermal lymphatics.",
"   </p>",
"   <p>",
"    The 2005 ASCO guidelines on SLND did not recommend the routine use of SLND in patients with locally advanced or inflammatory breast cancer for whom ALND was recommended to ensure locoregional control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/12\">",
"     12",
"    </a>",
"    ]. Consensus recommendations from an International Expert Panel published in 2010 considered inflammatory breast cancer to be the one of the few absolute contraindications to SLND [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/89\">",
"     89",
"    </a>",
"    ]. In addition, SLND was not recommended for T4 tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Neoadjuvant chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many women with large primary breast tumors are offered neoadjuvant chemotherapy prior to definitive locoregional therapy. The optimal timing for sentinel lymph node biopsy (SLND) in patients receiving neoadjuvant therapy has been debated, because some have reported a higher false negative rate for SLND performed after induction therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/122\">",
"     122",
"    </a>",
"    ]. As an example, a false negative rate of 13 percent was reported in one study of 111 women undergoing SLND in addition to completion axillary dissection after neoadjuvant chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/123\">",
"     123",
"    </a>",
"    ]. Other uncontrolled studies support the accuracy of SLND in such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/124-131\">",
"     124-131",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2011 NCCN guidelines recommend that SLND be performed prior to neoadjuvant chemotherapy because it provides valuable prognostic information for planning locoregional treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/15\">",
"     15",
"    </a>",
"    ]. Completion axillary dissection, if indicated, can be performed following chemotherapy at the time of definitive surgery. The ACOSOG trial Z1071, which is still accruing patients, is designed to answer the question of SLND accuracy after neoadjuvant chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/132\">",
"     132",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1529?source=see_link&amp;anchor=H1192519#H1192519\">",
"     \"Neoadjuvant systemic therapy for breast cancer: Response, subsequent treatment, and prognosis\", section on 'Nodal evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Multicentric disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies that evaluated the functional anatomy of lymphatic drainage support the theory that all quadrants of the breast drain into the same lymph node(s) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/133,134\">",
"     133,134",
"    </a>",
"    ]. Thus, subareolar and intradermal (rather than peritumoral) injection of radiolabeled colloid or blue dye render SLND feasible for patients with multicentric disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/133,135-137\">",
"     133,135-137",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/52/20296?source=see_link\">",
"     \"Sentinel lymph node biopsy in breast cancer: Techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The success of SLND for multicentric disease has been demonstrated in several studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/136,138\">",
"     136,138",
"    </a>",
"    ]. In a study of 142 women with multicentric breast cancer, SLND was successful in 91 percent, with a false negative rate of 4 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/138\">",
"     138",
"    </a>",
"    ]. However, the number of patients requiring completion ALND because of a positive SLN is higher in multicentric compared with unicentric disease. The likelihood of finding additional disease at the time of completion ALND is also higher with multicentric disease. The ASCO guidelines recommend SLND as appropriate for patients with multicentric disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Ductal carcinoma in situ",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most women with ductal carcinoma in situ (DCIS) do not require assessment of the axillary nodes, particularly if they are undergoing breast-conserving therapy. However, women with DCIS may be candidates for SLN mapping if they are undergoing mastectomy, because the performance of SLND will be impossible at a later time if invasive disease is found [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/12\">",
"     12",
"    </a>",
"    ]. An intact breast with its lymphatic plexus is necessary for injection of both the blue dye and the radioisotope tracers.",
"   </p>",
"   <p>",
"    Some recommend that SLND be considered in patients who are undergoing breast conserving therapy or mastectomy for DCIS only if the risk of node metastases is increased, as with extensive high-grade DCIS, a strong suspicion of invasive disease based upon ancillary imaging, or documented microinvasive disease in the core biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/12\">",
"     12",
"    </a>",
"    ]. However, if a partial mastectomy is performed and invasive disease is identified, a SLND can be done as a separate operation. This approach can minimize unnecessary morbidity, since SLND can be associated with complications. SLND is generally performed if microinvasion is found in the breast biopsy or if mastectomy is required for extensive or multifocal DCIS, where the risk of an occult invasive component is increased. If metastases are found on SLND, the disease stage would change accordingly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/139,140\">",
"     139,140",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/33/6680?source=see_link\">",
"     \"Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/43/37561?source=see_link\">",
"     \"Ductal carcinoma in situ: Treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/41/14998?source=see_link\">",
"     \"Microinvasive breast carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/45/24278?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging classification for breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety and test performance of SLND during pregnancy has not been fully evaluated. Supravital dyes such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/26/420?source=see_link\">",
"     isosulfan blue dye",
"    </a>",
"    should not be administered to pregnant women. Available data suggests that the dose of radiation to the fetus is minimal using radiocolloid during SLND and 2011 NCCN guidelines conclude that radiocolloid is safe during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/15,141,142\">",
"     15,141,142",
"    </a>",
"    ]. Nonetheless, 2005 guidelines from ASCO recommend against the use of SLND in pregnant women with early stage breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/51/17207?source=see_link\">",
"     \"Breast cancer during pregnancy and lactation: Epidemiology and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Previous breast or axillary surgery for nonmalignant conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The feasibility of SLND in women who have undergone other non-oncologic types of breast surgery such as reduction mammoplasty or augmentation with breast implants is unclear. The expert panel convened by ASCO did not make a recommendation for or against SLND in women who have had breast reduction or augmentation because of insufficient data [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/12\">",
"     12",
"    </a>",
"    ]. They suggested that if SLND were considered in this setting that it might best be performed with preoperative lymphoscintigraphy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/52/20296?source=see_link\">",
"     \"Sentinel lymph node biopsy in breast cancer: Techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10349110\">",
"    <span class=\"h2\">",
"     Recurrent breast cancer and previous axillary procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;SLND after previous axillary surgery has not been widely studied. Guidelines from ASCO recommend against SLND in women who have undergone prior axillary surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/12\">",
"     12",
"    </a>",
"    ]. However, there are accumulating reports of successful second SLND in patients with local breast cancer recurrence following a previous SLND",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    axillary lymph node dissection (ALND) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/143-146\">",
"     143-146",
"    </a>",
"    ]. The following review illustrates the effectiveness of a repeat lymphatic mapping and SLND:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective review of 150 patients with a previous SLND or ALND, lymphatic mapping (lymphoscintigraphy) using",
"      <sup>",
"       99m",
"      </sup>",
"      Tc-colloidal albumin identified a sentinel node in 63 percent and the sentinel node was successfully removed in 52 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/147\">",
"       147",
"      </a>",
"      ]. Aberrant drainage patterns were identified overall in 59 percent; patients with a previous ALND were more likely to have an aberrant pattern compared with patients undergoing a previous SLND (79 versus 25 percent, p&lt;0.001). Micrometastasis was identified in 18 patients (23 percent), and a confirmation ALND in all 18 patients identified no additional positive axillary lymph nodes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This practice is becoming more frequently employed and further study is indicated, including the optimal interval before repeat sentinel node biopsy should be attempted. Lymphoscintigraphy should be performed if repeat sentinel node biopsy is planned, given that these patients often have alternate drainage patterns. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34650?source=see_link\">",
"     \"Management of locoregional recurrence of breast cancer after breast conserving therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H365981762\">",
"    <span class=\"h1\">",
"     SLN MAPPING OF NONAXILLARY NODES",
"    </span>",
"    &nbsp;&mdash;&nbsp;SLN techniques can identify non-axillary metastases (eg, internal mammary nodes and intramammary nodes) in up to 43 percent of cases, depending upon the volume and type of colloid injected, injection technique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/148-150\">",
"     148-150",
"    </a>",
"    ], and primary tumor location and size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/151\">",
"     151",
"    </a>",
"    ]. Whether or not this is useful remains controversial, since the majority of the data regarding treatment decisions and outcomes comes from evaluation of only axillary nodes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Internal mammary nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positive IM nodes are most common with medial tumors over 2 cm in size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/152\">",
"     152",
"    </a>",
"    ]. Patients with axillary node negative disease will be found to have regional metastases to the IM nodes in 8 to 10 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/151,153-158\">",
"     151,153-158",
"    </a>",
"    ]. The diagnosis of positive IM nodes may affect treatment decisions regarding adjuvant systemic therapy and regional nodal irradiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/153\">",
"     153",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/46/39657?source=see_link&amp;anchor=H6#H6\">",
"     \"Techniques of breast and chest wall irradiation for early stage breast cancer\", section on 'The IM nodes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are limitations to the SLN technique for identification of IM nodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/53,151,153,154,156,159\">",
"     53,151,153,154,156,159",
"    </a>",
"    ]. SLND does not reliably identify involved IM LNs because of interference from radioactivity at the primary tumor site [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/53\">",
"     53",
"    </a>",
"    ]. There is a high rate of technical failure (20 to 39 percent) in patients with parasternal hot spots on lymphoscintigraphy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/156-158\">",
"     156-158",
"    </a>",
"    ], and hot spots in the IM region do not always represent tumor involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/151,154,160,161\">",
"     151,154,160,161",
"    </a>",
"    ]. In addition, some surgeons do not employ radiotracer injection and use only an intraoperative injection of blue dye to identify the sentinel nodes. Accordingly, additional noninvasive methods for IM node assessment may be helpful, including MRI or PET scanning, although these imaging modalities are unable to definitively identify positive nodes.",
"   </p>",
"   <p>",
"    The IM nodes are difficult to sample surgically if a positive hot spot is identified in this area [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/153\">",
"     153",
"    </a>",
"    ]. Although IM biopsy can be accomplished at the time of mastectomy by splitting the fibers of the pectoralis major, an IM node biopsy in a patient undergoing breast conserving surgery usually requires a second incision, which is cosmetically visible in many types of clothing. The procedure can be complicated by pneumothorax, pleural effusion or bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/154,156\">",
"     154,156",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The surgical management of the IM nodes remains controversial. There is no consensus on the need for IM nodal dissection in women with detection of an IM SLN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/12,13,162\">",
"     12,13,162",
"    </a>",
"    ]. Internal mammary nodes are not routinely dissected in patients undergoing breast conserving therapy or mastectomy with axillary lymph node dissection. Thus, in the absence of definitive data, dissection of the IM nodes with sentinel lymph node biopsy should be considered investigational.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Intramammary nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous case reports document identification of intramammary lymph nodes on SLND [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/163-167\">",
"     163-167",
"    </a>",
"    ], although few have explored the clinical significance of this finding. Intramammary LNs are present in 1 to 28 percent of women with breast cancer. Most series report a high likelihood of additional axillary nodal metastases when the intramammary nodes contain cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/168,169\">",
"     168,169",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/36/24138?source=see_link\">",
"     \"Diagnostic evaluation of women with suspected breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If intramammary nodes contain tumor, they have the same prognostic significance as a positive axillary LN with respect to staging. ALND should be considered for women with a positive intramammary LN on SLND, even if the axilla is clinically negative, because of the high rate of axillary LN involvement in these women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/47/36602/abstract/170\">",
"     170",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/59/6066?source=see_link\">",
"       \"Patient information: Sentinel lymph node biopsy for breast cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/56/12167?source=see_link\">",
"       \"Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The status of the axillary lymph nodes is one of the most important prognostic factors in women with early stage breast cancer. Histologic examination of removed lymph nodes is the most accurate method for assessing spread of disease to these nodes. Evaluation of the axilla is required for treatment decisions in patients with invasive breast cancer, and axillary lymph node dissection (ALND) remains the standard approach for women who are clinically node positive. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with early stage breast cancer who are clinically node negative, we recommend initial axillary evaluation with SLND rather than ALND (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients with ductal carcinoma in situ (DCIS) undergoing breast conserving surgery, we recommend not performing surgical evaluation of the axilla (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). For patients with extensive ductal carcinoma in situ undergoing a mastectomy, we suggest SLND (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Patients with DCIS extensive enough to require a mastectomy have a 20 percent chance of having occult invasive disease. If invasive disease is found and an SLND has not been performed, the patient will require an ALND. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Ductal carcinoma in situ'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When a SLND is not successful or when clinically suspicious nodes are present after all sentinel lymph nodes have been removed, an axillary dissection should be performed. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunohistochemical assessment (IHC) should be not be used as a routine method of evaluating sentinel nodes. IHC should be employed to definitively diagnose an area that is suspicious for, but not diagnostic of, lymph node metastases on H&amp;E. (See",
"      <a class=\"local\" href=\"#H6170711\">",
"       'Role of IHC and RT-PCR in sentinel node evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with clinically suspicious lymph nodes, preoperative axillary ultrasound (US) with fine needle aspiration (FNA) or core biopsy of suspicious areas provides a means to identify patients who have positive nodes, and thus need axillary lymph node dissection (ALND) rather than a SLND. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'The role of ultrasound in sentinel node evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For older patients, who are clinically node negative, in whom the nodal information will not affect adjuvant treatment decisions, we suggest not performing surgical evaluation of the axilla (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The decision about proceeding with ALND in women who are having breast conserving surgery for clinically node negative T1 or T2 breast cancer is based on the results of SLND (see",
"      <a class=\"local\" href=\"#H5456194\">",
"       'When should completion axillary dissection be performed?'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For women with a SLND that is negative or shows isolated tumor cells, we recommend not performing a completion ALND (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For women with three or more positive SLNs, we recommend performing ALND (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For women with",
"      <strong>",
"       one or two",
"      </strong>",
"      positive sentinel nodes, who will be treated with whole breast radiation, we suggest performing a completion ALND (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, for women with T1, hormone receptor positive tumors, who are comfortable with some level of uncertainty about long-term outcomes, avoidance of completion ALND is an option. When completion ALND is omitted in patients with a positive SLND, whole breast radiotherapy is indicated. If partial breast irradiation is planned, completion ALND should be performed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women who are having mastectomy rather than breast conserving therapy should be counseled that they will need completion ALND if the SLND is positive in order to determine the need for postmastectomy radiation. In some cases it may be preferable to perform the sentinel node biopsy as a separate procedure before the mastectomy, especially if reconstruction is desired, so that the proper sequencing of reconstruction and radiation can be arranged. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/3/41017?source=see_link\">",
"       \"Postmastectomy chest wall irradiation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The use of sentinel node biopsy in special circumstances including patients with locally advanced disease, patients undergoing neoadjuvant chemotherapy, pregnant patients, and those who have had prior breast or axillary surgery remains controversial. Inflammatory breast cancer is one of the few absolute contraindications to SLND",
"     </li>",
"     <li>",
"      We suggest performing a lymphoscintigraphy using",
"      <sup>",
"       99m",
"      </sup>",
"      Tc-colloidal albumin to identify the sentinel node in patients who have recurrent breast cancer and previous axillary procedures (SLND or ALND) rather than proceeding directly to an axillary dissection (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10349110\">",
"       'Recurrent breast cancer and previous axillary procedures'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/1\">",
"      Mabry H, Giuliano AE. Sentinel node mapping for breast cancer: progress to date and prospects for the future. Surg Oncol Clin N Am 2007; 16:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/2\">",
"      Lucci A, McCall LM, Beitsch PD, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol 2007; 25:3657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/3\">",
"      Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 2006; 98:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/4\">",
"      Fleissig A, Fallowfield LJ, Langridge CI, et al. Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat 2006; 95:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/5\">",
"      Latosinsky S, Dabbs K, Moffat F, Evidence-Based Reviews in Surgery Group. Canadian Association of General Surgeons and American College of Surgeons Evidence-Based Reviews in Surgery. 27. Quality-of-life outcomes with sentinel node biopsy versus standard axillary treatment in patients with operable breast cancer. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. Can J Surg 2008; 51:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/6\">",
"      Gill G, SNAC Trial Group of the Royal Australasian College of Surgeons (RACS) and NHMRC Clinical Trials Centre. Sentinel-lymph-node-based management or routine axillary clearance? One-year outcomes of sentinel node biopsy versus axillary clearance (SNAC): a randomized controlled surgical trial. Ann Surg Oncol 2009; 16:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/7\">",
"      Ashikaga T, Krag DN, Land SR, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol 2010; 102:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/8\">",
"      Land SR, Kopec JA, Julian TB, et al. Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32. J Clin Oncol 2010; 28:3929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/9\">",
"      Chen AY, Halpern MT, Schrag NM, et al. Disparities and trends in sentinel lymph node biopsy among early-stage breast cancer patients (1998-2005). J Natl Cancer Inst 2008; 100:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/10\">",
"      Quan ML, Hodgson N, Lovrics P, et al. National adoption of sentinel node biopsy for breast cancer: lessons learned from the Canadian experience. Breast J 2008; 14:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/11\">",
"      Heneghan HM, Prichard RS, Devaney A, et al. Evolution of breast cancer management in Ireland: a decade of change. BMC Surg 2009; 9:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/12\">",
"      Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005; 23:7703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/13\">",
"      Schwartz GF, Giuliano AE, Veronesi U, Consensus Conference Committee. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19-22, 2001, Philadelphia, Pennsylvania. Cancer 2002; 94:2542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/14\">",
"      Cantin J, Scarth H, Levine M, et al. Clinical practice guidelines for the care and treatment of breast cancer: 13. Sentinel lymph node biopsy. CMAJ 2001; 165:166.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/16\">",
"      Straver ME, Meijnen P, van Tienhoven G, et al. Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial. Ann Surg Oncol 2010; 17:1854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/17\">",
"      Veronesi U, Viale G, Paganelli G, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg 2010; 251:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/18\">",
"      Naik AM, Fey J, Gemignani M, et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures. Ann Surg 2004; 240:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/19\">",
"      Swenson KK, Mahipal A, Nissen MJ, et al. Axillary disease recurrence after sentinel lymph node dissection for breast carcinoma. Cancer 2005; 104:1834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/20\">",
"      Giuliano AE, Haigh PI, Brennan MB, et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol 2000; 18:2553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/21\">",
"      Roumen RM, Kuijt GP, Liem IH, van Beek MW. Treatment of 100 patients with sentinel node-negative breast cancer without further axillary dissection. Br J Surg 2001; 88:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/22\">",
"      Schrenk P, Hatzl-Griesenhofer M, Shamiyeh A, Waynad W. Follow-up of sentinel node negative breast cancer patients without axillary lymph node dissection. J Surg Oncol 2001; 77:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/23\">",
"      Blanchard DK, Donohue JH, Reynolds C, Grant CS. Relapse and morbidity in patients undergoing sentinel lymph node biopsy alone or with axillary dissection for breast cancer. Arch Surg 2003; 138:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/24\">",
"      Chung MA, Steinhoff MM, Cady B. Clinical axillary recurrence in breast cancer patients after a negative sentinel node biopsy. Am J Surg 2002; 184:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/25\">",
"      Reitsamer R, Peintinger F, Prokop E, et al. Sentinel lymph node biopsy alone without axillary lymph node dissection--follow up of sentinel lymph node negative breast cancer patients. Eur J Surg Oncol 2003; 29:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/26\">",
"      Badgwell BD, Povoski SP, Abdessalam SF, et al. Patterns of recurrence after sentinel lymph node biopsy for breast cancer. Ann Surg Oncol 2003; 10:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/27\">",
"      Andersson Y, de Boniface J, J&ouml;nsson PE, et al. Axillary recurrence rate 5 years after negative sentinel node biopsy for breast cancer. Br J Surg 2012; 99:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/28\">",
"      Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer--a multicenter validation study. N Engl J Med 1998; 339:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/29\">",
"      Krag D, Ashikaga T. The design of trials comparing sentinel-node surgery and axillary resection. N Engl J Med 2003; 349:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/30\">",
"      Weaver DL, Krag DN, Ashikaga T, et al. Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: a multicenter study. Cancer 2000; 88:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/31\">",
"      Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer 2006; 106:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/32\">",
"      Krag DN, Anderson SJ, Julian TB, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 2007; 8:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/33\">",
"      Krag DN, Julian TB, Harlow SP, et al. NSABP-32: Phase III, randomized trial comparing axillary resection with sentinal lymph node dissection: a description of the trial. Ann Surg Oncol 2004; 11:208S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/34\">",
"      Primary outcome results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients. ASCO 2010; Abstract LBA505. J Clin Oncol 2010; 28:18s (suppl; abstr LBA505).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/35\">",
"      Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 2010; 11:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/36\">",
"      Observation or standard axillary dissection after sentinel-node biopsy in breast cancer: Final results from the German KISS study. J Clin Oncol 2011; 29:Suppl; Abstr 1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/37\">",
"      Ciatto S, Brancato B, Risso G, et al. Accuracy of fine needle aspiration cytology (FNAC) of axillary lymph nodes as a triage test in breast cancer staging. Breast Cancer Res Treat 2007; 103:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/38\">",
"      Alkuwari E, Auger M. Accuracy of fine-needle aspiration cytology of axillary lymph nodes in breast cancer patients: a study of 115 cases with cytologic-histologic correlation. Cancer 2008; 114:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/39\">",
"      Sato K, Tamaki K, Tsuda H, et al. Utility of axillary ultrasound examination to select breast cancer patients suited for optimal sentinel node biopsy. Am J Surg 2004; 187:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/40\">",
"      Davis JT, Brill YM, Simmons S, et al. Ultrasound-guided fine-needle aspiration of clinically negative lymph nodes versus sentinel node mapping in patients at high risk for axillary metastasis. Ann Surg Oncol 2006; 13:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/41\">",
"      Hinson JL, McGrath P, Moore A, et al. The critical role of axillary ultrasound and aspiration biopsy in the management of breast cancer patients with clinically negative axilla. Ann Surg Oncol 2008; 15:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/42\">",
"      Krishnamurthy S, Sneige N, Bedi DG, et al. Role of ultrasound-guided fine-needle aspiration of indeterminate and suspicious axillary lymph nodes in the initial staging of breast carcinoma. Cancer 2002; 95:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/43\">",
"      van Rijk MC, Deurloo EE, Nieweg OE, et al. Ultrasonography and fine-needle aspiration cytology can spare breast cancer patients unnecessary sentinel lymph node biopsy. Ann Surg Oncol 2006; 13:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/44\">",
"      Koelliker SL, Chung MA, Mainiero MB, et al. Axillary lymph nodes: US-guided fine-needle aspiration for initial staging of breast cancer--correlation with primary tumor size. Radiology 2008; 246:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/45\">",
"      Holwitt DM, Swatske ME, Gillanders WE, et al. Scientific Presentation Award: The combination of axillary ultrasound and ultrasound-guided biopsy is an accurate predictor of axillary stage in clinically node-negative breast cancer patients. Am J Surg 2008; 196:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/46\">",
"      Topal U, Punar S, Tadelen I, Adim SB. Role of ultrasound-guided core needle biopsy of axillary lymph nodes in the initial staging of breast carcinoma. Eur J Radiol 2005; 56:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/47\">",
"      Britton PD, Goud A, Godward S, et al. Use of ultrasound-guided axillary node core biopsy in staging of early breast cancer. Eur Radiol 2009; 19:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/48\">",
"      Nathanson SD, Burke M, Slater R, Kapke A. Preoperative identification of the sentinel lymph node in breast cancer. Ann Surg Oncol 2007; 14:3102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/49\">",
"      Abe H, Schmidt RA, Kulkarni K, et al. Axillary lymph nodes suspicious for breast cancer metastasis: sampling with US-guided 14-gauge core-needle biopsy--clinical experience in 100 patients. Radiology 2009; 250:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/50\">",
"      Mills P, Sever A, Weeks J, et al. Axillary ultrasound assessment in primary breast cancer: an audit of 653 cases. Breast J 2010; 16:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/51\">",
"      Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997; 15:2345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/52\">",
"      Veronesi U, Paganelli G, Galimberti V, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 1997; 349:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/53\">",
"      Albertini JJ, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996; 276:1818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/54\">",
"      Borgstein PJ, Pijpers R, Comans EF, et al. Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J Am Coll Surg 1998; 186:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/55\">",
"      Turner RR, Chu KU, Qi K, et al. Pathologic features associated with nonsentinel lymph node metastases in patients with metastatic breast carcinoma in a sentinel lymph node. Cancer 2000; 89:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/56\">",
"      Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993; 2:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/57\">",
"      Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994; 220:391.",
"     </a>",
"    </li>",
"    <li>",
"     Lyman GH, Kim TY, Giuliano AE. A systematic review and meta-analysis of lymphatic mapping and sentinel node biopsy (SNB) in early-stage breast cancer (ESBC) (abstract 2001). Data presented at the 27th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 9, 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/59\">",
"      Carter BA, Page DL. Sentinel lymph node histopathology in breast cancer: minimal disease versus artifact. J Clin Oncol 2006; 24:1978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/60\">",
"      Youngson BJ, Liberman L, Rosen PP. Displacement of carcinomatous epithelium in surgical breast specimens following stereotaxic core biopsy. Am J Clin Pathol 1995; 103:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/61\">",
"      Douglas-Jones AG, Verghese A. Diagnostic difficulty arising from displaced epithelium after core biopsy in intracystic papillary lesions of the breast. J Clin Pathol 2002; 55:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/62\">",
"      Moore KH, Thaler HT, Tan LK, et al. Immunohistochemically detected tumor cells in the sentinel lymph nodes of patients with breast carcinoma: biologic metastasis or procedural artifact? Cancer 2004; 100:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/63\">",
"      Giuliano AE, Dale PS, Turner RR, et al. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995; 222:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/64\">",
"      Cronin-Fenton DP, Ries LA, Clegg LX, Edwards BK. Rising incidence rates of breast carcinoma with micrometastatic lymph node involvement. J Natl Cancer Inst 2007; 99:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/65\">",
"      PICKREN JW. Significance of occult metastases. A study of breast cancer. Cancer 1961; 14:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/66\">",
"      Fisher ER, Swamidoss S, Lee CH, et al. Detection and significance of occult axillary node metastases in patients with invasive breast cancer. Cancer 1978; 42:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/67\">",
"      Rosen PP, Saigo PE, Braun DW Jr, et al. Occult axillary lymph node metastases from breast cancers with intramammary lymphatic tumor emboli. Am J Surg Pathol 1982; 6:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/68\">",
"      Wilkinson EJ, Hause LL, Hoffman RG, et al. Occult axillary lymph node metastases in invasive breast carcinoma: characteristics of the primary tumor and significance of the metastases. Pathol Annu 1982; 17 Pt 2:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/69\">",
"      de Mascarel I, MacGrogan G, Picot V, Mathoulin-Pelissier S. Prognostic significance of immunohistochemically detected breast cancer node metastases in 218 patients. Br J Cancer 2002; 87:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/70\">",
"      Gobardhan PD, Elias SG, Madsen EV, et al. Prognostic value of micrometastases in sentinel lymph nodes of patients with breast carcinoma: a cohort study. Ann Oncol 2009; 20:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/71\">",
"      Milgrom S, Cody H, Tan L, et al. Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment. Ann Surg Oncol 2012; 19:3762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/72\">",
"      Prognostic importance of occult axillary lymph node micrometastases from breast cancers. International (Ludwig) Breast Cancer Study Group. Lancet 1990; 335:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/73\">",
"      Cote RJ, Peterson HF, Chaiwun B, et al. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet 1999; 354:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/74\">",
"      Hainsworth PJ, Tjandra JJ, Stillwell RG, et al. Detection and significance of occult metastases in node-negative breast cancer. Br J Surg 1993; 80:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/75\">",
"      McGuckin MA, Cummings MC, Walsh MD, et al. Occult axillary node metastases in breast cancer: their detection and prognostic significance. Br J Cancer 1996; 73:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/76\">",
"      Clare SE, Sener SF, Wilkens W, et al. Prognostic significance of occult lymph node metastases in node-negative breast cancer. Ann Surg Oncol 1997; 4:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/77\">",
"      Chen SL, Hoehne FM, Giuliano AE. The prognostic significance of micrometastases in breast cancer: a SEER population-based analysis. Ann Surg Oncol 2007; 14:3378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/78\">",
"      Reed J, Rosman M, Verbanac KM, et al. Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer: 10-year analysis of patients enrolled in the prospective East Carolina University/Anne Arundel Medical Center Sentinel Node Multicenter Study. J Am Coll Surg 2009; 208:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/79\">",
"      Pepels MJ, de Boer M, Bult P, et al. Regional recurrence in breast cancer patients with sentinel node micrometastases and isolated tumor cells. Ann Surg 2012; 255:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/80\">",
"      Weaver DL, Ashikaga T, Krag DN, et al. Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med 2011; 364:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/81\">",
"      Viale G, Maiorano E, Mazzarol G, et al. Histologic detection and clinical implications of micrometastases in axillary sentinel lymph nodes for patients with breast carcinoma. Cancer 2001; 92:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/82\">",
"      Houvenaeghel G, Nos C, Mignotte H, et al. Micrometastases in sentinel lymph node in a multicentric study: predictive factors of nonsentinel lymph node involvement--Groupe des Chirurgiens de la Federation des Centres de Lutte Contre le Cancer. J Clin Oncol 2006; 24:1814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/83\">",
"      Dabbs DJ, Fung M, Landsittel D, et al. Sentinel lymph node micrometastasis as a predictor of axillary tumor burden. Breast J 2004; 10:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/84\">",
"      Changsri C, Prakash S, Sandweiss L, Bose S. Prediction of additional axillary metastasis of breast cancer following sentinel lymph node surgery. Breast J 2004; 10:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/85\">",
"      McCready DR, Yong WS, Ng AK, et al. Influence of the new AJCC breast cancer staging system on sentinel lymph node positivity and false-negative rates. J Natl Cancer Inst 2004; 96:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/86\">",
"      Chagpar A, Middleton LP, Sahin AA, et al. Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer 2005; 103:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/87\">",
"      Pugliese MS, Beatty JD, Tickman RJ, et al. Impact and outcomes of routine microstaging of sentinel lymph nodes in breast cancer: significance of the pN0(i+) and pN1mi categories. Ann Surg Oncol 2009; 16:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/88\">",
"      Giuliano AE, Hawes D, Ballman KV, et al. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA 2011; 306:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/89\">",
"      Kaufmann M, Morrow M, von Minckwitz G, et al. Locoregional treatment of primary breast cancer: consensus recommendations from an International Expert Panel. Cancer 2010; 116:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/90\">",
"      Cserni G, Bianchi S, Vezzosi V, et al. The value of cytokeratin immunohistochemistry in the evaluation of axillary sentinel lymph nodes in patients with lobular breast carcinoma. J Clin Pathol 2006; 59:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/91\">",
"      Weinberg ES, Dickson D, White L, et al. Cytokeratin staining for intraoperative evaluation of sentinel lymph nodes in patients with invasive lobular carcinoma. Am J Surg 2004; 188:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/92\">",
"      Sanuki N, Takeda A, Amemiya A, et al. Outcomes of clinically node-negative breast cancer without axillary dissection: can preserved axilla be safely treated with radiation after a positive sentinel node biopsy? Clin Breast Cancer 2013; 13:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/93\">",
"      Kapoor NS, Sim MS, Lin J, Giuliano AE. Long-term Outcome of Patients Managed With Sentinel Lymph Node Biopsy Alone for Node-Negative Invasive Breast Cancer. Arch Surg 2012; 147:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/94\">",
"      Olson JA Jr, McCall LM, Beitsch P, et al. Impact of immediate versus delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: results from American College of Surgeons Oncology Group Trials Z0010 and Z0011. J Clin Oncol 2008; 26:3530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/95\">",
"      Carlson GW, Wood WC. Management of axillary lymph node metastasis in breast cancer: making progress. JAMA 2011; 305:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/96\">",
"      Chagpar AB. Clinical significance of minimal sentinel node involvement and management options. Surg Oncol Clin N Am 2010; 19:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/97\">",
"      Hwang RF, Gonzalez-Angulo AM, Yi M, et al. Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer 2007; 110:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/98\">",
"      Fant JS, Grant MD, Knox SM, et al. Preliminary outcome analysis in patients with breast cancer and a positive sentinel lymph node who declined axillary dissection. Ann Surg Oncol 2003; 10:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/99\">",
"      Jeruss JS, Winchester DJ, Sener SF, et al. Axillary recurrence after sentinel node biopsy. Ann Surg Oncol 2005; 12:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/100\">",
"      Francissen CM, Dings PJ, van Dalen T, et al. Axillary recurrence after a tumor-positive sentinel lymph node biopsy without axillary treatment: a review of the literature. Ann Surg Oncol 2012; 19:4140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/101\">",
"      Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 2010; 252:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/102\">",
"      Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011; 305:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/103\">",
"      Latosinsky S, Berrang TS, Cutter CS, et al. CAGS and ACS Evidence Based Reviews in Surgery. 40. Axillary dissection versus no axillary dissection in women with invasive breast cancer and sentinel node metastasis. Can J Surg 2012; 55:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/104\">",
"      Giuliano AE, Morrow M, Duggal S, Julian TB. Should ACOSOG Z0011 change practice with respect to axillary lymph node dissection for a positive sentinel lymph node biopsy in breast cancer? Clin Exp Metastasis 2012; 29:687.",
"     </a>",
"    </li>",
"    <li>",
"     Galimberti V, Cole BF, Zurrida S, et al. [S3-1] Update of International Breast Cancer Study Group Trial 23-01 To Compare Axillary Dissection Versus No Axillary Dissection in Patients with Clinically Node Negative Breast Cancer and Micrometastases in the Sentinel Node. file://www.abstracts2view.com/sabcs11/view.php?nu=SABCS11L_150 (Accessed on January 17, 2013).",
"    </li>",
"    <li>",
"     Whelan TJ, Olivotto I, Ackerman JW, et al.  NCIC-CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer. J Clin Oncol 2011 29:(Suppl; abstr LBA1003).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/107\">",
"      NCIC-CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer. J Clin Oncol 2011; 29:LBA1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/108\">",
"      Weaver DL, Le UP, Dupuis SL, et al. Metastasis detection in sentinel lymph nodes: comparison of a limited widely spaced (NSABP protocol B-32) and a comprehensive narrowly spaced paraffin block sectioning strategy. Am J Surg Pathol 2009; 33:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/109\">",
"      Galimberti V. International Breast Cancer Study Group Trial of sentinel node biopsy. J Clin Oncol 2006; 24:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/110\">",
"      Katz A, Niemierko A, Gage I, et al. Can axillary dissection be avoided in patients with sentinel lymph node metastasis? J Surg Oncol 2006; 93:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/111\">",
"      Dauphine CE, Haukoos JS, Vargas MP, et al. Evaluation of three scoring systems predicting non sentinel node metastasis in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol 2007; 14:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/112\">",
"      Gur AS, Unal B, Johnson R, et al. Predictive probability of four different breast cancer nomograms for nonsentinel axillary lymph node metastasis in positive sentinel node biopsy. J Am Coll Surg 2009; 208:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/113\">",
"      Van Zee KJ, Manasseh DM, Bevilacqua JL, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol 2003; 10:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/114\">",
"      Lambert LA, Ayers GD, Hwang RF, et al. Validation of a breast cancer nomogram for predicting nonsentinel lymph node metastases after a positive sentinel node biopsy. Ann Surg Oncol 2006; 13:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/115\">",
"      Katz A, Smith BL, Golshan M, et al. Nomogram for the prediction of having four or more involved nodes for sentinel lymph node-positive breast cancer. J Clin Oncol 2008; 26:2093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/116\">",
"      Mittendorf EA, Hunt KK, Boughey JC, et al. Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. Ann Surg 2012; 255:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/117\">",
"      Boughey JC, Bedrosian I, Meric-Bernstam F, et al. Comparative analysis of sentinel lymph node operation in male and female breast cancer patients. J Am Coll Surg 2006; 203:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/118\">",
"      Chung MH, Ye W, Giuliano AE. Role for sentinel lymph node dissection in the management of large (&gt; or = 5 cm) invasive breast cancer. Ann Surg Oncol 2001; 8:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/119\">",
"      Wong SL, Chao C, Edwards MJ, et al. Accuracy of sentinel lymph node biopsy for patients with T2 and T3 breast cancers. Am Surg 2001; 67:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/120\">",
"      Hidar S, Bibi M, Gharbi O, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy in inflammatory breast cancer. Int J Surg 2009; 7:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/121\">",
"      Singletary SE. Surgical management of inflammatory breast cancer. Semin Oncol 2008; 35:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/122\">",
"      Nason KS, Anderson BO, Byrd DR, et al. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer 2000; 89:2187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/123\">",
"      Tausch C, Steger GG, Haid A, et al. Sentinel node biopsy after primary chemotherapy in breast cancer: a note of caution from results of ABCSG-14. Breast J 2011; 17:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/124\">",
"      Stearns V, Ewing CA, Slack R, et al. Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol 2002; 9:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/125\">",
"      Newman EA, Sabel MS, Nees AV, et al. Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation. Ann Surg Oncol 2007; 14:2946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/126\">",
"      Breslin TM, Cohen L, Sahin A, et al. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2000; 18:3480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/127\">",
"      Tausch C, Konstantiniuk P, Kugler F, et al. Sentinel lymph node biopsy after preoperative chemotherapy for breast cancer: findings from the Austrian Sentinel Node Study Group. Ann Surg Oncol 2008; 15:3378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/128\">",
"      Julian TB, Patel N, Dusi D, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer. Am J Surg 2001; 182:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/129\">",
"      Bedrosian I, Reynolds C, Mick R, et al. Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors. Cancer 2000; 88:2540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/130\">",
"      Balch GC, Mithani SK, Richards KR, et al. Lymphatic mapping and sentinel lymphadenectomy after preoperative therapy for stage II and III breast cancer. Ann Surg Oncol 2003; 10:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/131\">",
"      Mamounas EP, Brown A, Anderson S, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2005; 23:2694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/132\">",
"      Santin BJ, Cutter SC. Is the surgical generalist falling out of favor? Bull Am Coll Surg 2009; 94:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/133\">",
"      Klimberg VS, Rubio IT, Henry R, et al. Subareolar versus peritumoral injection for location of the sentinel lymph node. Ann Surg 1999; 229:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/134\">",
"      Borgstein PJ, Meijer S, Pijpers RJ, van Diest PJ. Functional lymphatic anatomy for sentinel node biopsy in breast cancer: echoes from the past and the periareolar blue method. Ann Surg 2000; 232:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/135\">",
"      McMasters KM, Wong SL, Martin RC 2nd, et al. Dermal injection of radioactive colloid is superior to peritumoral injection for breast cancer sentinel lymph node biopsy: results of a multiinstitutional study. Ann Surg 2001; 233:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/136\">",
"      Schrenk P, Wayand W. Sentinel-node biopsy in axillary lymph-node staging for patients with multicentric breast cancer. Lancet 2001; 357:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/137\">",
"      Kern KA. Concordance and validation study of sentinel lymph node biopsy for breast cancer using subareolar injection of blue dye and technetium 99m sulfur colloid. J Am Coll Surg 2002; 195:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/138\">",
"      Knauer M, Konstantiniuk P, Haid A, et al. Multicentric breast cancer: a new indication for sentinel node biopsy--a multi-institutional validation study. J Clin Oncol 2006; 24:3374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/139\">",
"      Weaver DL. Occult \"micrometastases\" in ductal carcinoma in situ: investigative implications for sentinel lymph node biopsy. Cancer 2003; 98:2083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/140\">",
"      Lara JF, Young SM, Velilla RE, et al. The relevance of occult axillary micrometastasis in ductal carcinoma in situ: a clinicopathologic study with long-term follow-up. Cancer 2003; 98:2105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/141\">",
"      Gentilini O, Cremonesi M, Toesca A, et al. Sentinel lymph node biopsy in pregnant patients with breast cancer. Eur J Nucl Med Mol Imaging 2010; 37:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/142\">",
"      Spanheimer PM, Graham MM, Sugg SL, et al. Measurement of uterine radiation exposure from lymphoscintigraphy indicates safety of sentinel lymph node biopsy during pregnancy. Ann Surg Oncol 2009; 16:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/143\">",
"      Intra M, Trifir&ograve; G, Viale G, et al. Second biopsy of axillary sentinel lymph node for reappearing breast cancer after previous sentinel lymph node biopsy. Ann Surg Oncol 2005; 12:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/144\">",
"      Taback B, Nguyen P, Hansen N, et al. Sentinel lymph node biopsy for local recurrence of breast cancer after breast-conserving therapy. Ann Surg Oncol 2006; 13:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/145\">",
"      Newman EA, Cimmino VM, Sabel MS, et al. Lymphatic mapping and sentinel lymph node biopsy for patients with local recurrence after breast-conservation therapy. Ann Surg Oncol 2006; 13:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/146\">",
"      Maaskant-Braat AJ, Voogd AC, Roumen RM, Nieuwenhuijzen GA. Repeat sentinel node biopsy in patients with locally recurrent breast cancer: a systematic review and meta-analysis of the literature. Breast Cancer Res Treat 2013; 138:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/147\">",
"      Maaskant-Braat AJ, Roumen RM, Voogd AC, et al. Sentinel Node and Recurrent Breast Cancer (SNARB): results of a nationwide registration study. Ann Surg Oncol 2013; 20:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/148\">",
"      Shimazu K, Tamaki Y, Taguchi T, et al. Lymphoscintigraphic visualization of internal mammary nodes with subtumoral injection of radiocolloid in patients with breast cancer. Ann Surg 2003; 237:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/149\">",
"      Tanis PJ, Deurloo EE, Vald&eacute;s Olmos RA, et al. Single intralesional tracer dose for radio-guided excision of clinically occult breast cancer and sentinel node. Ann Surg Oncol 2001; 8:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/150\">",
"      Doting MH, Jansen L, Nieweg OE, et al. Lymphatic mapping with intralesional tracer administration in breast carcinoma patients. Cancer 2000; 88:2546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/151\">",
"      Harlow S, Krag D, Weaver D, Ashikaga T. Extra-Axillary Sentinel Lymph Nodes in Breast Cancer. Breast Cancer 1999; 6:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/152\">",
"      Shahar KH, Buchholz TA, Delpassand E, et al. Lower and central tumor location correlates with lymphoscintigraphy drainage to the internal mammary lymph nodes in breast carcinoma. Cancer 2005; 103:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/153\">",
"      Chen RC, Lin NU, Golshan M, et al. Internal mammary nodes in breast cancer: diagnosis and implications for patient management -- a systematic review. J Clin Oncol 2008; 26:4981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/154\">",
"      Mansel RE, Goyal A, Newcombe RG, ALMANAC Trialists Group. Internal mammary node drainage and its role in sentinel lymph node biopsy: the initial ALMANAC experience. Clin Breast Cancer 2004; 5:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/155\">",
"      Klauber-DeMore N, Bevilacqua JL, Van Zee KJ, et al. Comprehensive review of the management of internal mammary lymph node metastases in breast cancer. J Am Coll Surg 2001; 193:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/156\">",
"      van der Ent FW, Kengen RA, van der Pol HA, et al. Halsted revisited: internal mammary sentinel lymph node biopsy in breast cancer. Ann Surg 2001; 234:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/157\">",
"      Tanis PJ, Nieweg OE, Vald&eacute;s Olmos RA, et al. Impact of non-axillary sentinel node biopsy on staging and treatment of breast cancer patients. Br J Cancer 2002; 87:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/158\">",
"      Heuts EM, van der Ent FW, von Meyenfeldt MF, Voogd AC. Internal mammary lymph drainage and sentinel node biopsy in breast cancer - A study on 1008 patients. Eur J Surg Oncol 2009; 35:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/159\">",
"      Noguchi M, Tsugawa K, Miwa K. Internal mammary chain sentinel lymph node identification in breast cancer. J Surg Oncol 2000; 73:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/160\">",
"      Fabry HF, Mutsaers PG, Meijer S, et al. Clinical relevance of parasternal uptake in sentinel node procedure for breast cancer. J Surg Oncol 2004; 87:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/161\">",
"      Carcoforo P, Sortini D, Feggi L, et al. Clinical and therapeutic importance of sentinel node biopsy of the internal mammary chain in patients with breast cancer: a single-center study with long-term follow-up. Ann Surg Oncol 2006; 13:1338.",
"     </a>",
"    </li>",
"    <li>",
"     Breast Section of the Royal Australasian College of Surgeons: sentinel node biopsy in breast cancer 2005. www.nbcc.org.au/media/Sentinel_node_biopsy.html (Accessed on November 05, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/163\">",
"      Gajdos C, Bleiweiss IJ, Drossman S, Tartter PI. Breast cancer in an intramammary sentinel node. Breast J 2001; 7:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/164\">",
"      Tytler I, Hayes A, Kissin M. Intramammary sentinel nodes in early breast cancer: can we find them and do they matter? Eur J Surg Oncol 2003; 29:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/165\">",
"      Jansen L, Doting MH, Rutgers EJ, et al. Clinical relevance of sentinel lymph nodes outside the axilla in patients with breast cancer. Br J Surg 2000; 87:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/166\">",
"      Upponi S, Kalra S, Poultsidis A, et al. The significance of intramammary nodes in primary breast cancer. Eur J Surg Oncol 2001; 27:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/167\">",
"      Rull M, Fraile M, Alastru&eacute; A, et al. Histologically invaded intramammary sentinel node, but no metastases found on axillary dissection. Eur J Surg 1999; 165:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/168\">",
"      Intra M, Garcia-Etienne CA, Renne G, et al. When sentinel lymph node is intramammary. Ann Surg Oncol 2008; 15:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/169\">",
"      Pugliese MS, Stempel MM, Cody HS 3rd, et al. Surgical management of the axilla: do intramammary nodes matter? Am J Surg 2009; 198:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/47/36602/abstract/170\">",
"      Shen J, Hunt KK, Mirza NQ, et al. Intramammary lymph node metastases are an independent predictor of poor outcome in patients with breast carcinoma. Cancer 2004; 101:1330.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 810 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-4D580CFE0A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_47_36602=[""].join("\n");
var outline_f35_47_36602=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2642382\">",
"      DEVELOPMENT AND VALIDATION OF THE SLNB TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      THE ROLE OF ULTRASOUND IN SENTINEL NODE EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MANAGEMENT OF SLN METASTASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6264723\">",
"      Isolated tumor cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1583503\">",
"      Micrometastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6264783\">",
"      Macrometastases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6170711\">",
"      - Role of IHC and RT-PCR in sentinel node evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1583667\">",
"      Role of IHC in invasive lobular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5456194\">",
"      When should completion axillary dissection be performed?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13373789\">",
"      - ACOSOG Z-0011 trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13373796\">",
"      - IBCSG 23-01 trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13373821\">",
"      - NCIC-CTG MA. 20 trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13373803\">",
"      - NCCN",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13373810\">",
"      - Mastectomy procedure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Predictive nomograms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SLNB IN SPECIAL CIRCUMSTANCES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Male breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Locally advanced and inflammatory breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Neoadjuvant chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Multicentric disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Ductal carcinoma in situ",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Previous breast or axillary surgery for nonmalignant conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10349110\">",
"      Recurrent breast cancer and previous axillary procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H365981762\">",
"      SLN MAPPING OF NONAXILLARY NODES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Internal mammary nodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Intramammary nodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/810\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/810|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?43/18/44326\" title=\"diagnostic image 1\">",
"      Mammogram of early breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?15/24/15748\" title=\"diagnostic image 2\">",
"      Ultrasound of early breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?24/32/25088\" title=\"diagnostic image 3\">",
"      MRI of early breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?15/19/15664\" title=\"diagnostic image 4\">",
"      Ultrasound image of normal axillary lymph node",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?43/23/44403\" title=\"diagnostic image 5\">",
"      Ultrasound image of abnormal axillary lymph node",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?25/26/26019\" title=\"diagnostic image 6\">",
"      Ultraound image of Doppler flow in abnormal axillary lymph node",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/810|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/11/21687\" title=\"picture 1\">",
"      Lymphoscintigraphy of early breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/810|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/61/5085\" title=\"table 1\">",
"      Breast cancer specific survival according to stage at diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/59/24504?source=related_link\">",
"      Breast biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/51/17207?source=related_link\">",
"      Breast cancer during pregnancy and lactation: Epidemiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/36/26186?source=related_link\">",
"      Breast cancer in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/33/6680?source=related_link\">",
"      Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/29/39386?source=related_link\">",
"      Breast reconstruction in women with breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/52/1866?source=related_link\">",
"      Clinical manifestations and diagnosis of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/36/24138?source=related_link\">",
"      Diagnostic evaluation of women with suspected breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/43/37561?source=related_link\">",
"      Ductal carcinoma in situ: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/58/13226?source=related_link\">",
"      General principles on the treatment of early stage and locally advanced breast cancer in older women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34650?source=related_link\">",
"      Management of locoregional recurrence of breast cancer after breast conserving therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/52/42825?source=related_link\">",
"      Management of the regional lymph nodes in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/41/14998?source=related_link\">",
"      Microinvasive breast carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1529?source=related_link\">",
"      Neoadjuvant systemic therapy for breast cancer: Response, subsequent treatment, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/56/12167?source=related_link\">",
"      Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/59/6066?source=related_link\">",
"      Patient information: Sentinel lymph node biopsy for breast cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/3/41017?source=related_link\">",
"      Postmastectomy chest wall irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/52/20296?source=related_link\">",
"      Sentinel lymph node biopsy in breast cancer: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/46/39657?source=related_link\">",
"      Techniques of breast and chest wall irradiation for early stage breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/45/24278?source=related_link\">",
"      Tumor node metastasis (TNM) staging classification for breast cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_47_36603="Hypertensive herbal ingredients";
var content_f35_47_36603=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F68095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F68095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hypertensive herbal ingredients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bayberry",
"       </td>",
"       <td>",
"        Hypertensive, myricitrin mineralocorticoid side effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Broom",
"       </td>",
"       <td>",
"        Hypertensive, alkaloid effect, stated to be contraindicated in hypertensive individuals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Capsicum",
"       </td>",
"       <td>",
"        Hypertensive, increased catecholamine secretion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cohosh, blue",
"       </td>",
"       <td>",
"        Hypertensive, methylcytisine has nicotinic action, alkaloid effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cola",
"       </td>",
"       <td>",
"        Hypertensive, caffeine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coltsfoot",
"       </td>",
"       <td>",
"        Hypertensive, pressor activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gentian",
"       </td>",
"       <td>",
"        Stated to be contraindicated in hypertensive individuals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ginger",
"       </td>",
"       <td>",
"        Hypertensive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ginseng, Panax",
"       </td>",
"       <td>",
"        Hypertensive, human and in vivo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liquorice",
"       </td>",
"       <td>",
"        Hypertensive, mineralocorticoid side effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mat&eacute;",
"       </td>",
"       <td>",
"        Hypertensive, caffeine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vervain",
"       </td>",
"       <td>",
"        Hypertensive",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from Newall CA, Anderson LA, Phillipson JD. Herbal Medicines: A Guide for Health-Care Professionals, The Pharmaceutical Press, London 1996, p. 282.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_47_36603=[""].join("\n");
var outline_f35_47_36603=null;
var title_f35_47_36604="Ingredient label terms for sesame";
var content_f35_47_36604=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F56144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F56144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    How to read an ingredient label for a sesame-free diet",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       The following ingredients indicate the presence of sesame protein:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sesame flour",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sesame oil",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sesame seeds",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sesame paste - Tahini",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Foreign terms that indicate the presence of sesame protein:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Benne/benne seed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gingelly",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sesamol/sesamolina",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sesamum indicum",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sim sim",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tahina",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Til",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Other foods that may contain the presence of sesame seed protein:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bakery products such as breads, rolls, and bagels",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bread crumbs, breadings, and prepared breaded products",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Breakfast cereals such as Granola, Muesli, and Kashi brand cereals",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Snacks such as tortillas chips, pretzels, rice cakes, crackers, and Japanese snack mixes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       High protein bars, energy bars, and low carbohydrate products",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Salad dressings, soups, spice mixes, and marinades",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Exotic, ethnic, vegetarian, and \"natural\" foods that commonly have sesame seed protein as an ingredient:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Baba Ghanoush",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Falafel",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Goma-dofu (Japanese custard)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Halvah",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hummus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pasteli (Greek dessert)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sushi",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vegetarian burgers",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Japanese and Chinese dipping sauces and marinades",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Cross contamination with sesame may occur in bakeries, bagel shops, and Chinese and Japanese restaurants.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; As sesame is not considered a major allergen by the FDA, it may be a hidden ingredient in vague ingredient terms such as \"flavoring\", \"natural flavoring\", or \"spices\". Please call the manufacturer to ask if sesame is included in the flavoring or spice of a product.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Some herbal drinks may contain sesame including Aqua Libra, a British herbal beverage.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &bull; Sesame may also be used in soaps, cosmetics, creams, and massage oils where it may be listed as Sesamum indicum.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_47_36604=[""].join("\n");
var outline_f35_47_36604=null;
var title_f35_47_36605="Obstructive flow volume curve";
var content_f35_47_36605=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 480px\">",
"   <div class=\"ttl\">",
"    Obstructive defect",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 460px; height: 333px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The flow-volume curve in a&nbsp;patient with an obstructive defect (red) demonstrates scooping of the descending portion of the expiratory limb compared to predicted (blue). The forced expiratory flow rate is reduced over the middle 50 percent of the forced vital capacity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_47_36605=[""].join("\n");
var outline_f35_47_36605=null;
var title_f35_47_36606="Treatment approach ITP";
var content_f35_47_36606=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F54047&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F54047&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 627px\">",
"   <div class=\"ttl\">",
"    Treatment approach in immune thrombocytopenia (ITP) in adults",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 607px; height: 396px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This diagram represents a",
"    <strong>",
"     simplified",
"    </strong>",
"    approach to the treatment of patients with ITP. A threshold platelet count of 30,000/microL for clinical decisions, rather than a range of platelet counts, is presented, but clinical symptoms and patients' concerns are more important for treatment decisions.",
"    <br>",
"     Note: Only four of the many possible treatments of ITP are described in this algorithm. As an example, for first line treatment IVIG may be used instead of glucocorticoids when a more rapid increase in platelet count is required. IVIG or anti-D (in appropriate patients) may be used as first line treatment if glucocorticoid use is contraindicated.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_47_36606=[""].join("\n");
var outline_f35_47_36606=null;
var title_f35_47_36607="IDUS catheter";
var content_f35_47_36607=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intraductal ultrasound catheter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 436px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intraductal ultrasound catheter positioned over a guidewire seen at the tip of an duodenoscope.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Micheal J Levy, MD, Enrique Vazquez-Sequeiros, MD, and Maurits J Wiersema, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_47_36607=[""].join("\n");
var outline_f35_47_36607=null;
 